

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS


IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: C07D 463/00, A61K 31/435	A1	(11) International Publication Number: WO 93/25551 (43) International Publication Date: 23 December 1993 (23.12.93)
(21) International Application Number: PCT/GB93/01092 (22) International Filing Date: 26 May 1993 (26.05.93) (30) Priority data: 9212609.3 13 June 1992 (13.06.92) GB (71) Applicant (for all designated States except US): SMITH-KLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): BURTON, George [GB/GB]; NAYLOR, Antoinette [GB/GB]; SmithKline Beecham Pharmaceuticals, Brockham Park, Betchworth, Surrey RH3 7AJ (GB).		(74) Agent: WALKER, Ralph, Francis; SmithKline Beecham, Corporate Patents, Great Burgh, Yew Tree Bottom Road, Epsom, Surrey KT18 5XQ (GB). (81) Designated States: AU, CA, JP, KR, NZ, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>

(54) Title: 3-SUBSTITUTED CARBACEPHEMS

(I)

(57) Abstract

A compound of formula (I) or a salt thereof, wherein R^1 is hydrogen, methoxy or formamido; R^2 is an acyl group, in particular that of an antibacterially active cephalosporin; CO_2R^3 is a carboxy group or a carboxylate anion, or R^3 is a readily removable carboxy protecting group or a pharmaceutically acceptable salt-forming group or *in vivo* hydrolysable ester group; R^4 represents hydrogen or up to four substituents, which may be present on any of the carbon atoms in the ring system shown, selected from alkyl, alkenyl, alkynyl, alkoxy, hydroxy, halogen, amino, alkylamino, acylamino, dialkylamino, CO_2R , $CONR_2$, SO_2NR_2 where R is hydrogen or alkyl, aryl and heterocyclyl, which may be the same or different and wherein any R^4 alkyl substituent is optionally substituted by one or more substituents selected from the list from which R^4 is selected; Y is O, S, SO or SO_2 ; and m is 1 or 2, a process for its preparation, use as an antibiotic and intermediates thereto.

FOR THE PURPOSES OF INFORMATION ONLY


Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

3-SUBSTITUTED CARBACEPHEMS

This invention relates to novel β -lactam compounds, their preparation and their use, and in particular to a novel class of cephems. These compounds have antibacterial properties, and are therefore of use in the treatment of bacterial infections in humans and animals caused by a wide range of organisms.

PCT/GB91/01228 (WO 92/01696) generically discloses cephems of general formula (A):




(A)

wherein R^1 , R^2 , R^3 and R^4 are various substituents, m is 1 or 2 and X is S, SO, SO_2 , O or CH_2 .

We have found a particularly advantageous class of carbacephems bearing a cyclic ether or thio-ether substituent at the 3-position of the cephem nucleus, and which are not specifically disclosed in WO92/01696.

The present invention provides a compound of formula (I) or a salt thereof:



(I)

wherein:

- R^1 is hydrogen, methoxy or formamido;
- R^2 is an acyl group, in particular that of an antibacterially active cephalosporin;
- CO_2R^3 is a carboxy group or a carboxylate anion, or R^3 is a readily removable carboxy protecting group or a pharmaceutically acceptable salt-forming group or *in vivo* hydrolysable ester group;
- R^4 represents hydrogen or up to four substituents, which may be present on any of the carbon atoms in the ring system shown, selected from alkyl, alkenyl, alkynyl, alkoxy, hydroxy, halogen, amino, alkylamino, acylamino, dialkylamino, CO_2R , $CONR_2$, SO_2NR_2 where R is hydrogen or alkyl, aryl and heterocyclyl, which may be the same or different and wherein any R^4 alkyl substituent is optionally substituted by one or


more substituents selected from the list from which R^4 is selected;

Y is O, S, SO or SO_2 ; and m is 1 or 2.

The bonding carbon atom of the cyclic ether or thio-ether moiety which links the ring to the cephem nucleus is generally asymmetric. The present invention includes either stereoisomer, as well as mixtures of both isomers.

In compounds of formula (I) wherein R^1 is formamido, the formamido group can exist in conformations wherein the hydrogen atoms of the $-NH-CHO$ moiety are *cis*- or *trans*-; of these the *cis* conformation normally predominates.

Preferred compounds within formula (I) are compounds of formula (Ia) or pharmaceutically acceptable salts or pharmaceutically acceptable *in vivo* hydrolysable esters thereof:



(Ia)

wherein R^1 , R^2 , R^4 , m and y are as defined with respect to formula (I) and the group CO_2R^6 is CO_2R^3 where CO_2R^3 is a carboxy group or a carboxylate anion.

Accordingly, the present invention provides a compound of formula (Ia) or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, for use as a therapeutic agent, and in particular an *in vivo* hydrolysable ester thereof for use as an orally administrable therapeutic agent.

The present invention further provides a compound of formula (Ia) or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, for use in the treatment of bacterial infections, more particularly an *in vivo* hydrolysable ester thereof for use in the oral treatment of bacterial infections.

The present invention also includes a method of treating bacterial infections in humans and animals which comprises the administration of a therapeutically effective amount of an antibiotic compound of the formula (Ia) or a pharmaceutically acceptable *in vivo* hydrolysable ester thereof, in particular the oral administration of a therapeutically effective amount of an *in vivo* hydrolysable ester.

In addition, the present invention includes the use of a compound of formula (Ia) or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, for the manufacture of a medicament for the treatment of bacterial infections, in particular the use of an *in vivo* hydrolysable ester for the manufacture of a medicament for the oral treatment of bacterial infections.

Those compounds of the formula (I) wherein R^3 is a readily removable

carboxy protecting group other than a pharmaceutically acceptable *in vivo* hydrolysable ester or which are in non-pharmaceutically acceptable salt form are primarily useful as intermediates in the preparation of compounds of the formula (Ia) or a pharmaceutically acceptable salt or pharmaceutically acceptable *in vivo*

5 hydrolysable ester thereof.


Suitable readily removable carboxy protecting groups for the group R^3 include groups forming ester derivatives of the carboxylic acid, including *in vivo* hydrolysable esters. The derivative is preferably one which may readily be cleaved *in vivo*.

10 Also included within the scope of the invention are salts and carboxy-protected derivatives, including *in vivo* hydrolysable esters, of any carboxy groups that may be present as optional substituents in compounds of formula (I) or (Ia). Also included within the scope of the invention are acid addition salts of any amino group or substituted amino group that may be present as optional substituents
15 in compounds of formula (I) or (Ia).

Suitable ester-forming carboxyl-protecting groups are those which may be removed under conventional conditions. Such groups for R^3 include benzyl, p-methoxybenzyl, benzoylmethyl, p-nitrobenzyl, 4-pyridylmethyl, 2,2,2-trichloroethyl, 2,2,2-tribromoethyl, t-butyl, t-amyl, allyl, diphenylmethyl, triphenylmethyl, adamantyl, 2-benzyloxyphenyl, 4-methylthiophenyl, tetrahydrofur-2-yl, tetrahydropyran-2-yl, pentachlorophenyl, acetonyl, p-toluenesulphonylethyl, methoxymethyl, 2-trimethylsilylethyl, a silyl, stannyl or phosphorus- containing group, an oxime radical of formula $-N=CHR^7$ where R^7 is aryl or heterocyclic, or an *in vivo* hydrolysable ester radical such as defined below.
20

25 A carboxyl group may be regenerated from any of the above esters by usual methods appropriate to the particular R^3 group, for example, acid- and base-catalysed hydrolysis, or by enzymically-catalysed hydrolysis, or by hydrogenolysis under conditions wherein the remainder of the molecule is substantially unaffected.

Examples of suitable pharmaceutically acceptable *in vivo* hydrolysable ester
30 groups include those which break down readily in the human body to leave the parent acid or its salt. Suitable ester groups of this type include those of part formulae (i), (ii), (iii), (iv) and (v):




- wherein R^a is hydrogen, (C₁₋₆) alkyl, (C₃₋₇) cycloalkyl, methyl, or phenyl, R^b is (C₁₋₆) alkyl, (C₁₋₆) alkoxy, phenyl, benzyl, (C₃₋₇) cycloalkyl, (C₃₋₇) cycloalkyloxy, (C₁₋₆) alkyl (C₃₋₇) cycloalkyl, 1-amino (C₁₋₆) alkyl, or 1-((C₁₋₆) alkyl)amino (C₁₋₆) alkyl; or R^a and R^b together form a 1,2-phenylene group optionally substituted by one or two methoxy groups; R^c represents (C₁₋₆) alkylene optionally substituted with a methyl or ethyl group and R^d and R^e independently represent (C₁₋₆) alkyl; R^f represents (C₁₋₆) alkyl; R^g represents hydrogen or phenyl optionally substituted by up to three groups selected from halogen, (C₁₋₆) alkyl, or (C₁₋₆) alkoxy; Q is oxygen or NH; R^h is hydrogen or (C₁₋₆) alkyl; R^i is hydrogen, (C₁₋₆) alkyl optionally substituted by halogen, (C₂₋₆) alkenyl, (C₁₋₆) alkoxycarbonyl, aryl or heteroaryl; or R^h and R^i together form (C₁₋₆) alkylene; R^j represents hydrogen, (C₁₋₆) alkyl or (C₁₋₆) alkoxycarbonyl; and R^k represents (C₁₋₈) alkyl, (C₁₋₈) alkoxy, (C₁₋₆) alkoxy((C₁₋₆))alkoxy or aryl.

- Examples of suitable *in vivo* hydrolysable ester groups include, for example, acyloxyalkyl groups such as acetoxymethyl, pivaloyloxymethyl, α -acetoxylethyl,

α -pivaloyloxyethyl, 1-(cyclohexylcarbonyloxy)prop-1-yl, and (1-aminoethyl)carbonyloxymethyl; alkoxy carbonyloxyalkyl groups, such as ethoxycarbonyloxymethyl, α -ethoxycarbonyloxyethyl and propoxycarbonyloxyethyl; dialkylaminoalkyl especially di-loweralkylamino alkyl groups such as

5 dimethylaminomethyl, dimethylaminoethyl, diethylaminomethyl or diethylaminoethyl; 2-(alkoxycarbonyl)-2-alkenyl groups such as 2-(isobutoxycarbonyl)pent-2-enyl and 2-(ethoxycarbonyl)but-2-enyl; lactone groups such as phthalidyl and dimethoxyphthalidyl; and esters linked to a second β -lactam antibiotic or to a β -lactamase inhibitor.

- 10 A further suitable pharmaceutically acceptable *in vivo* hydrolysable ester group is that of the formula:



wherein R^m is hydrogen, (C_{1-6}) alkyl or phenyl.

A preferred *in vivo* hydrolysable ester group is the pivaloyloxymethyl ester.

- 15 Suitable pharmaceutically acceptable salts of the carboxy group of the compound of formula (I) include metal salts, eg aluminium, alkali metal salts such as sodium or potassium, especially sodium, alkaline earth metal salts such as calcium or magnesium, and ammonium or substituted ammonium salts, for example those with
- 20 lower alkylamines such as triethylamine, hydroxy-lower alkylamines such as 2-hydroxyethylamine, bis-(2-hydroxyethyl)amine or tris-(2-hydroxyethyl)-amine, cycloalkylamines such as dicyclohexylamine, or with procaine, dibenzylamine, *N,N*-dibenzylethylene-diamine, 1-phenamine, *N*-methylmorpholine, *N*-ethylpiperidine, *N*-benzyl- β -phenethylamine, dehydroabietylamine, *N,N*-bisdehydro-abietylamine, ethylenediamine, or bases of the pyridine type such as
- 25 pyridine, collidine or quinoline, or other amines which have been used to form salts with known penicillins and cephalosporins. Other useful salts include the lithium salt and silver salt. Salts of formula (I) may be prepared by salt exchange in conventional manner.

- 30 In compounds of formula (I) or (Ia), the group Y may be an oxidised sulphur atom, i.e. a sulfoxide (SO) or sulphone (SO₂) group. When Y is a sulfoxide group it will be understood that α - and β -isomers may exist; both such isomers are encompassed within the scope of the present invention.

Preferably Y is O or S, in particular O.

Advantageously, R^1 is hydrogen.

- 35 Suitably, the cyclic ether or thio-ether at the 3-position of the cephalosporin

- nucleus is unsubstituted or substituted by up to three substituents R^4 , selected from (C₁₋₆) alkyl, for example methyl, (C₁₋₆) alkoxy, for example methoxy, (C₁₋₆) alkoxycarbonyl for example methoxycarbonyl, (C₁₋₆) alkoxy (C₁₋₆) alkyl, for example methoxymethyl, and (C₁₋₆) alkanoyloxy (C₁₋₆) alkyl, for example acetoxymethyl. Preferably the cyclic ether or thio-ether at the 3-position of the cephalosporin nucleus is unsubstituted.

Preferably m is 1.

Suitably the cyclic ether at the 3-position of the cephalosporin nucleus is a tetrahydrofuran-2-yl group.

- 10 Preferably the cyclic thio-ether is bonded to the cephalosporin nucleus at a ring carbon adjacent to the oxygen or sulphur heteroatom.

Suitable acyl groups R^2 include those of formulae (a) - (f):



- wherein p is 0, 1 or 2; m is 0, 1 or 2; A_1 is (C₁₋₆) alkyl, substituted (C₁₋₆) alkyl
 15 wherein the substituents may be as for R^4 above, (C₃₋₆) cycloalkyl, cyclohexenyl, cyclohexadienyl, an aryl (including heteroaryl) group, such as phenyl, substituted phenyl, thienyl, pyridyl, or an optionally substituted thiazolyl group, a (C₁₋₆)

akylthio group or (C₁₋₆) alkyloxy; X₁ is a hydrogen or halogen atom, a carboxylic acid, carboxylic ester, sulphonic acid, azido, tetrazolyl, hydroxy, acyloxy, amino, ureido, acylamino, heterocyclylamino, guanidino or acylureido group; A₂ is an aryl group, for example a phenyl, 2,6-dimethoxyphenyl, 2-alkoxy-1-naphthyl,
 5 3-arylisoxazolyl, or a 3-aryl-5-methylisoxazolyl group, such as 3-(2-chloro-6-fluorophenyl)-5-methylisoxazol-4-yl; a substituted alkyl group; or a substituted dithietane; X₂ is a -CH₂OCH₂-, -CH₂SCH₂- or alkylene group; X₃ is an oxygen or sulphur atom; A₃ is an aryl or heteroaryl group such as phenyl, substituted phenyl, furyl, aminothiazolyl or aminothiadiazolyl in which the amino group is
 10 optionally protected; and A₄ is hydrogen, (C₁₋₆)alkyl, (C₃₋₈) cycloalkyl, (C₃₋₈) cycloalkyl(C₁₋₆)alkyl, (C₁₋₆) alkoxycarbonyl(C₁₋₆) alkyl, (C₂₋₆) alkenyl, carboxy(C₁₋₆)alkyl, (C₂₋₆) alkynyl, aryl or (C₁₋₆)alkyl substituted by up to three aryl groups.

Suitably when R² is a group (a), A₁ is (C₁₋₆) alkyl, (C₃₋₆) cycloalkyl,
 15 cyclohexenyl, cyclohexadienyl, phenyl, substituted phenyl (eg substituted as for "aryl" above) such as hydroxyphenyl, thienyl or pyridyl; and X₁ is a hydrogen or halogen atom, or a carboxy, carboxylic ester, azido, tetrazolyl, hydroxy, acyloxy, optionally protected amino, ureido, guanidino or acylureido group.

Suitably when R² is a group of formula (d), A₂ is phenyl, X₃ is oxygen and p
 20 is O.

Alternatively when R² is a group of formula (e) or (f)
 suitable values for the group A₃ include those commonly found in antibacterially active cephalosporins containing a hydroxyimino, substituted hydroxyimino or vinyl group in the side chain attached to position 7 of the cephalosporin nucleus, for
 25 example phenyl, thien-2-yl, thien-3-yl, fur-2-yl, fur-3-yl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, 5-amino-1,2,4-thiadiazol-3-yl and 2-aminothiazol-4-yl in each of which the amino group is optionally protected.

Preferred groups for A₃ include phenyl, 2-aminothiazol-4-yl, fur-2-yl, thien-2-yl, 2-(2-chloroacetamido)thiazol-4-yl, 2-tritylamino-thiazol-4-yl,
 30 5-amino-1,2,4-thiadiazol-3-yl and 4-aminopyrimid-2-yl.

In compounds of formula (Ia) a preferred acyl group R² is one of formula (e), having a group, A₃ which is 2-aminothiazol-4-yl.

Suitable values for the group A₄ include hydrogen, methyl, ethyl, cyclopropylmethyl, triphenylmethyl (trityl), cyclobutyl, cyclopentyl, cyclohexyl,
 35 cycloheptyl, cyclooctyl, phenyl, carboxymethyl, carboxypropyl and t-butoxycarbonylmethyl.

Preferred values for A₄ in compounds of formula (Ia) include methyl and hydrogen.


It will be appreciated that compounds of the invention wherein R² is a group

of formula (e) or (f) can exist as *syn* and *anti* (or *E* and *Z*) isomers or mixtures thereof. Both isomers are encompassed within the scope of this invention.

Preferably the compounds of the invention wherein R^2 is a group of formula (e) have the *syn* configuration (i.e. have the group OA_4 *syn* to the amide linkage) or are enriched in that isomer.

Similarly, when R^2 is a group of formula (f), the group A_4 is preferably *cis* to the amide linkage, i.e. when group (f) is 2-amino-thiazol-4-yl, the *Z*-configuration is preferred.

Preferably in formula (I) and (Ia) if the 3-position substituent is a tetrahydrofuran-2-yl ring system the compound has the configuration:



Certain compounds of the invention include an amino group which may be protected. Suitable amino protecting groups are those well known in the art which may be removed under conventional conditions without disruption of the remainder of the molecule.

Examples of amino protecting groups include (C₁₋₆) alkanoyl; benzoyl; benzyl optionally substituted in the phenyl ring by one or two substituents selected from (C₁₋₄) alkyl, (C₁₋₄) alkoxy, trifluoromethyl, halogen, or nitro; (C₁₋₄) alkoxycarbonyl; benzyloxycarbonyl or trityl (ie triphenylmethyl) substituted as for benzyl above; allyloxycarbonyl, trichloroethoxycarbonyl or chloroacetyl.

When used herein the term 'aryl' includes phenyl and naphthyl, each optionally substituted with up to five, preferably up to three, groups selected from halogen, mercapto, (C₁₋₆) alkyl, phenyl, (C₁₋₆) alkoxy, hydroxy(C₁₋₆)alkyl, mercapto(C₁₋₆)alkyl, halo(C₁₋₆) alkyl, hydroxy, amino, nitro, carboxy, (C₁₋₆)alkylcarbonyloxy, (C₁₋₆)alkoxycarbonyl, formyl, or (C₁₋₆)alkylcarbonyl groups.

The terms 'heterocyclyl' and 'heterocyclic' as used herein include aromatic and non-aromatic, single and fused, rings suitably containing up to four hetero-atoms in each ring selected from oxygen, nitrogen and sulphur, which rings may be unsubstituted or substituted by, for example, up to three groups selected from halogen, (C₁₋₆)alkyl, (C₁₋₆)alkoxy, halo(C₁₋₆)alkyl, hydroxy, carboxy, carboxy salts, carboxy esters such as (C₁₋₆)alkoxycarbonyl, (C₁₋₆)alkoxycarbonyl(C₁₋₆)alkyl, aryl, and oxo groups. Each heterocyclic ring suitably has from 4 to 7, preferably 5 or 6, ring atoms. The term 'heteroaryl' refers to heteroaromatic

heterocyclic rings. A fused heterocyclic ring system may include carbocyclic rings and need include only one heterocyclic ring. Compounds within the invention containing a heterocyclyl group may occur in two or more tautomeric forms depending on the nature of the heterocyclyl group; all such tautomeric forms are
5 included within the scope of the invention.

The term 'heteroaryl' as used herein means a heteroaromatic heterocyclic ring or ring system, suitably having 5 or 6 ring atoms in each ring.

When used herein the terms 'alkyl', 'alkenyl', 'alkynyl' and 'alkoxy' include straight and branched chain groups containing from 1 to 6 carbon atoms, such as
10 methyl, ethyl, propyl and butyl. A particular alkyl group is methyl.

When used herein the term 'halogen' refers to fluorine, chlorine, bromine and iodine.

Some of the compounds of this invention may be crystallised or recrystallised from solvents such as organic solvents. In such cases solvates may be formed. This
15 invention includes within its scope stoichiometric solvates including hydrates as well as compounds containing variable amounts of water that may be produced by processes such as lyophilisation.

Since the antibiotic compounds of the invention are intended for use in pharmaceutical compositions it will readily be understood that they are each provided
20 in substantially pure form, for example at least 60% pure, more suitably at least 75% pure and preferably at least 85%, especially at least 95% pure, particularly at least 98% pure (% are on a weight for weight basis). Impure preparations of the compounds may be used for preparing the more pure forms used in the pharmaceutical compositions; these less pure preparations of the compounds should
25 contain at least 1%, more suitably at least 5% and preferably from 10 to 49% of a compound of the formula (I) or salt thereof.

Specific compounds within this invention of formula (Ia) include the following pharmaceutically acceptable carboxylic acids, salts and *in-vivo* hydrolysable esters:

30 Pivaloyloxymethyl (6*R*,7*S*)-7-[2-(2-aminothiazol-4-yl)-2-(*Z*)-methoxyiminoacetamido]-[(*S*)-tetrahydrofuran-2-yl]-1-carba-1-dethiaceph-3-em-4-carboxylate,

Sodium (6*R*,7*S*)-7-[2-(2-aminothiazol-4-yl)-2-(*Z*)-methoxyiminoacetamido]-3-[(*S*)-tetrahydrofuran-2-yl]-1-carba-1-dethiaceph-3-em-4-carboxylate,

4-Methoxybenzyl (6*R*,7*S*)-7-phenylacetamido-3-[(*R* and *S*)-tetrahydrofuran-2-yl]-1-carb-1-dethiaceph-3-em-4-carboxylate,
35

4-Methoxybenzyl (6*R*,7*S*)-7-phthalimido-3-[(*S*)-tetrahydrofuran-2-yl]-1-carba-1-dethiaceph-3-em-4-carboxylate,

Sodium (6*R*,7*S*)-7-[2-(2-aminothiazol-4-yl)-2-(*Z*)-prop-2-yloxyiminoacetamido]-3-[(2*S*)-tetrahydrofuran-2-yl]-1-carba-1-dethiaceph-3-em-4-carboxylate,

4-Methoxybenzyl (6*R*,7*S*)-7-[2-(2-aminothiazol-4-yl)-2-(*Z*)-prop-2-yloxyiminoacetamido]-3-[(2*S*)-tetrahydrofuran-2-yl]-1-carba-1-dethiaceph-3-em-4-carboxylate,


Sodium (6*R*,7*S*)-7-[2-(2-aminothiazol-4-yl)-2-(*Z*)-hydroxyiminoacetamido]-3-[(2*S*)-tetrahydrofuran-2-yl]-1-carba-1-dethiaceph-3-em-4-carboxylate,

4-Methoxybenzyl (6*R*,7*S*)-7-[2-(2-aminothiazol-4-yl)-2-(*Z*)-hydroxyiminoacetamido]-3-[(2*S*)-tetrahydrofuran-2-yl]-1-carba-1-dethiaceph-3-em-4-carboxylate,

Sodium (6*R*,7*S*)-7-[2-(2-aminothiazol-4-yl)-2-(*Z*)-difluoromethoxyiminoacetamido]-3-[(2*S*)-tetrahydrofuran-2-yl]-1-carba-1-dethiaceph-3-em-4-carboxylate,

The present invention provides a process for the preparation of a compound of formula (I) or (Ia) as defined above in which CO_2R^3 is a carboxy group or carboxylate anion or R^3 is a pharmaceutically acceptable salt-forming group or *in vivo* hydrolysable ester group, wherein a compound of formula (I) as defined above in which R^3 is a carboxy protecting group has its group CO_2R^3 replaced by a group CO_2R^3 which is a carboxy group or a carboxylate anion, or in which R^3 is a pharmaceutically acceptable salt-forming group or *in-vivo* hydrolysable ester group.

The present invention further provides a process for the preparation of a compound of formula (I), which process comprises treating a compound of formula (II) or a salt thereof:



(II)

wherein R^1 , CO_2R^3 , R^4 , m , and Y are as hereinbefore defined, wherein any reactive groups may be protected, and wherein the amino group is optionally substituted with a group which permits acylation to take place; with an acid of formula (III) or a *N*-acylating derivative thereof:



(III)

wherein R^2 is the acyl group as defined with respect to formula (I) and wherein any reactive groups may be protected; and thereafter, if necessary or desired, carrying out one or more of the following steps:

i) removing any protecting groups;

- ii) converting the group CO_2R^3 into a different group CO_2R^3 ;
- iii) converting the group R^2 into a different group R^2 ;
- iv) converting the group Y into a different group Y, for example S into SO or SO_2 ;
- 5 v) converting the product into a salt or ester.

Acids of formula (III) may be prepared by methods known in the art, or methods analogous to such processes. Suitable processes include those described, for example, in UK Patent 2 107 307 B, UK Patent Specification No. 1,536,281, and U.K. Patent Specification No. 1,508,064.

- 10 Suitable groups which permit acylation to take place and which are optionally present on the amino group of the starting material of the formula (II) include *N*-silyl, *N*-stannyl and *N*-phosphorus groups, for example trialkylsilyl groups such as trimethylsilyl, trialkyltin groups such as tri-*n*-butyltin, groups of formula $-\text{P.R}^7\text{R}^8$ wherein R^7 is an alkyl, haloalkyl, aryl, aralkyl, alkoxy, haloalkyl, aryl, aralkyl, alkoxy, haloalkoxy, aryloxy, aralkyloxy or dialkylamino group, R^8 is the same as R^7 or is halogen or R^7 and R^8 together form a ring; suitable such phosphorus groups being $-\text{P}(\text{OC}_2\text{H}_5)_2$, $-\text{P}(\text{C}_2\text{H}_5)_2$,
- 15



- 20 A group which may optionally be introduced onto the amino group in the compound of formula (II) is trimethylsilyl.

- Advantageously the silylation reaction may be carried out *in situ*, prior to the acylation reaction, with a silylating agent that does not require concomitant addition of base. Suitable silylating agents include, for example, *N*-(trimethylsilyl)-acetamide, *N,O*-bis-(trimethylsilyl)acetamide, *N,O*-bis(trimethylsilyl)-trifluoroacetamide, *N*-methyl-*N*-trimethylsilylacetamide, *N*-methyl-*N*-trimethylsilyl-trifluoroacetamide, *N,N*-bis(trimethylsilyl)urea, and *N,O*-bis(trimethylsilyl)carbamate. A preferred silylating agent is *N,O*-bis(trimethylsilyl)acetamide. The silylation reaction may suitably be carried out in an inert, anhydrous organic solvent such as dichloromethane at room temperature or at an elevated temperature, for example 30 - 60°C, preferably 40 - 50°C.
- 25
- 30

The above process may optionally be carried out in the presence of a small quantity, for example 0.1 equivalents, of a silyl halide, for example a $\text{tri}(\text{C}_{1-6})$ alkylsilyl halide, especially trimethylsilyl chloride.

- 35 A reactive *N*-acylating derivative of the acid (III) is employed in the above process. The choice of reactive derivative will of course be influenced by the chemical nature of the substituents of the acid.

Suitable N-acylating derivatives include an acid halide, preferably the acid chloride or bromide or alternatively a symmetrical or mixed anhydride. The acylation may be effected in the presence of an acid binding agent for example, tertiary amine (such as pyridine or dimethylaniline), molecular sieves, an inorganic base (such as calcium carbonate or sodium bicarbonate) or an oxirane, which binds hydrogen halide liberated in the acylation reaction. The oxirane is preferably a (C₁₋₆)-1,2-alkylene oxide - such as ethylene oxide or propylene oxide. The acylation reaction using an acid halide may be carried out at a temperature in the range -50°C to +50°C, preferably -20°C to +20°C, in aqueous or non-aqueous media such as water, acetone, tetrahydrofuran, ethyl acetate, dimethylacetamide, dimethylformamide, acetonitrile, dichloromethane, 1,2-dichloroethane, or mixtures thereof. Alternatively, the reaction may be carried out in an unstable emulsion of water-immiscible solvent, especially an aliphatic ester or ketone, such as methyl isobutyl ketone or butyl acetate. The acylation with acid halide or anhydride is suitably carried out in the presence of a basic catalyst such as pyridine or 2,6-lutidine.

Acid halides may be prepared by reacting the acid (III) or a salt or a reactive derivative thereof with a halogenating (eg chlorinating or brominating) agent such as phosphorus pentachloride, thionyl chloride, oxalyl chloride or phosgene.

Suitable mixed anhydrides are anhydrides with, for example, carbonic acid monoesters, trimethyl acetic acid, thioacetic acid, diphenylacetic acid, benzoic acid, phosphorus acids (such as phosphoric, phosphorous, and phosphinic acids) or aromatic or aliphatic sulphonic acids (such as p-toluenesulphonic acid or methanesulphonic acid).

Alternative N-acylating derivatives of acid (III) are the acid azide, or activated esters such as esters with 2-mercaptopyridine, cyanomethanol, p-nitrophenol, 2,4-dinitrophenol, thiophenol, halophenols, including pentachlorophenol, monomethoxyphenol, N-hydroxy succinimide, N-hydroxybenzotriazole, or 8-hydroxyquinoline; or amides such as N-acylsaccharins, N-acylthiazolidin-2-thione or N-acylphthalimides; or an alkylidene iminoester prepared by reaction of the acid (III) with an oxime.

Other reactive N-acylating derivatives of the acid (III) include the reactive intermediates formed by reaction *in situ* with a condensing agent such as a carbodiimide, for example, N,N'-diethyl-, dipropyl- or diisopropylcarbodiimide, N,N'-di-cyclohexyl-carbodiimide, or N-ethyl-N'-[3-(dimethylamino)propyl]-carbodiimide; a suitable carbonyl compound, for example, N,N'-carbonyldiimidazole or N,N'-carbonyldi-triazole; an isoxazolinium salt, for example, N-ethyl-5-phenylisoxazolinium-3-sulphonate or N-t-butyl-5-methylisoxazolinium perchlorate; or an N-alkoxycarbonyl 2-alkoxy-1,2-dihydroquinoline, such as N-ethoxycarbonyl 2-ethoxy-1,2-dihydroquinoline. Other condensing agents include

Lewis acids (for example $\text{BBr}_3 - \text{C}_6\text{H}_6$);

or a phosphoric acid condensing agent such as diethylphosphorylcyanide. The condensation reaction is preferably carried out in an organic reaction medium, for example, methylene chloride, dimethylformamide, acetonitrile, alcohol, benzene,
5 dioxan or tetrahydrofuran.

A further method of forming the *N*-acylating derivative of the acid of formula (III) is to treat the acid of formula (III) with a solution or suspension preformed by addition of a carbonyl halide, preferably oxalyl chloride, or a phosphoryl halide such as phosphorus oxychloride, to a halogenated hydrocarbon solvent, preferably
10 dichloromethane, containing a lower acyl tertiary amide, preferably *N,N*-dimethylformamide. The *N*-acylating derivative of the acid of formula (III) so derived may then be caused to react with a compound of formula (II). The acylation reaction may conveniently be carried out at -40° to $+30^\circ\text{C}$, if desired in the presence of an acid binding agent such as pyridine. A catalyst such as
15 4-dimethylaminopyridine may optionally also be added. A preferred solvent for the above acylation reaction is dichloromethane.

The optional removal of protecting group (i), the optional conversion of CO_2R^3 (ii), the optional conversion (iii) of R^2 to a different R^2 , CO_2R^3 to a different CO_2R^3 and (iv), Y to a different Y, and (v) the optional formation of a salt
20 or ester, may be carried out using methods well known in the art of cephalosporin and penicillin chemistry.

For example, when the group Y is S, SO, or SO_2 , the group Y may be converted into a different group Y by methods of oxidation or reduction well known in the art of cephalosporin and penicillin synthesis, as described, for example, in
25 European Patent Application Publication No. 0 114 752. For example, sulphoxides (in which Y is SO) may be prepared from the corresponding sulphide (in which Y is S) by oxidation with a suitable oxidising agent, for example an organic peracid such as *m*-chloroperbenzoic acid.


A reduction step is generally effected by processes well known in the art of β -lactam chemistry, for example using phosphorus trichloride in dimethylformamide.
30

For example, removal of protecting groups may be carried out by any convenient method known in the art such that unwanted side reactions are minimised. When for example R^3 is the protecting group *p*-methoxybenzyl, this group may suitably be removed by treatment of the protected compound with aluminium
35 chloride in the presence of anisole. Separation of unwanted by-products may be carried out using standard methods.

Compounds of formula (I), (Ia) and (II) may be made by further processes of this invention.

For example in one further process "route A" a compound of formula (II) may

be formed by cyclising a compound of formula (IV):



(IV)


where R^1 , R^3 , R^4 , and m are as defined in formula (I), R^{21} is a group R^2NH or a group which can be converted into R^2NH and R^x is alkyl.

Suitably R^{21} may be a substituted or protected amino group such as phenylacetamido, from which the substituting or protecting group may be removed in a deprotection step. In the case of phenylacetamido this deprotection may be carried out using the known Delft cleavage reaction. Suitable reaction conditions for Delft cleavage include treatment with phosphorus pentachloride and N-methylmorpholine at reduced temperature. Alternatively R^{21} may be a group which may be converted into or replaced by an amino group, for example a phthalimido group, which may be replaced by an amino group by treatment with a hydrazine such as methyl hydrazine.

Suitably R^x may be n-butyl.

Suitably the cyclisation reaction may be carried out by refluxing in an organic solvent such as toluene in the presence of benzoic acid.


Compounds of formula (IV) may for example be prepared from compounds of formula (V):



(V)

where R^1 , R^{21} , R^3 , R^4 and m are as defined above, by for example replacement of the hydroxy group shown with a halogen, preferably chlorine, using for example a halogenating agent such as thionyl chloride in the presence of a base such as lutidine, followed by reaction of the chloro compound with PR^x_3 .


Compounds of formula (V) may for example be prepared from compounds of formula (VI):



(VI)

- 5 where R^1 , R^{21} , R^4 and m are or defined above, by for example reaction with the appropriate R^3 -glyoxylate, for example *p*-methoxybenzyl glyoxylate, for example at 0°C in the presence of a base such as triethylamine.

Compounds of formula (VI) may for example be prepared from compounds of formula (VII)




(VII)

10

where R^1 , R^{21} , R^4 and m are as defined above, where PG is an amino protecting group such as *p*-methoxyphenyl, by removal of this protecting group, eg in the case of *p*-methoxyphenyl using aqueous ceric ammonium nitrate.


- 15 Compounds of formula (VII) may for example be prepared from compounds of formula (VIII):



(VIII)


- 20 where R^1 , R^{21} , R^4 , m and PG are as defined above, by for example hydrogenation of the alkene using Pd/C and hydrogen.

Compounds of formula (VIII) may for example be prepared from compounds of formula (IX):



(IX)


where R^1 , R^{21} and PG are as defined above by reaction with a compound of formula (X)



(IX)

where R^y is an organic group such as phenyl, Y, m and R^4 are as defined above, for example by stirring together in a solvent at room temperature.


Compounds of formula (X) may be prepared from known (see WO 92/01696) compounds of formula (X):



(XI)

where Y, R^4 are m are as defined above by reaction with a compound R^y_3P where R^y is an organic group such as phenyl.


Compounds of formula (IX) may for example be prepared from compounds of formula (XII):



(XII)

where R^1 , R^{21} and PG are as defined above by reaction with periodic acid in a suitable solvent such as a tetrahydrofuran/water mixture.

Compounds of formula (XII) may for example be prepared from compounds of formula (XIII):




(XIII)

where R^1 and PG are as defined above, by reaction with an acid of formula R^{21} COOH or an acylating derivative thereof such as an acyl chloride, for example phenylacetyl chloride.


5

Compounds of formula (XIII) may for example be prepared from the known compound L-(S)-glyceraldehyde acetonide (XVI):




(XVI)

- 10 which may be prepared as described in C. Hubschwerlen "Synthesis" (1986), (962), by treatment of (XVI) with p-anisidine for example in a solvent such as dichloromethane to form a compound of formula (XV):



(XV)

- 15 where PG is a protecting group as defined above. The compound of formula (XV) may then be cyclised to form the acetidinone (XIV):




(XIV)

- 20 where Ft represents phthalimido, by reaction of the compound of formula (XV) with phthalimidoacetyl chloride. The phthalimido group Ft may be removed and replaced by an amino group in a compound of formula (XIII) by treatment of the compound

(XIV) with methylhydrazine.


For example in a second further process "route B", a compound of formula (II) in the form of a mixture of diastereoisomers, which may be resolved, may be for example prepared from a compound of formula (XVII):



5

(XVII)


where R^{21} and R^3 are as defined above and Tf represents trifluoromethanesulphonyloxy, by reaction with a compound of formula (XVIII):



10

(XVIII)

where Y, R^4 and m are as defined above. Compounds of formula (XVIII) may be prepared for example from known (J. Amer. Chem. Soc. (1988) 110 842) compounds of formula (XIX)




15

(XIX)

where R^4 , Y and m are as defined above, and R^z is alkyl, by reaction with n-butyl lithium then with a copper (I) bromide dimethylsulphide complex.

Compounds of formula (XVII) may for example be prepared from compounds of formula (XX):




20

(XX)

where R^{21} and R^3 are as defined above, by reflux with a rhodium (II) catalyst, followed by cooling and sequential treatment with a base such as N, N-diisopropylethylamine then trifluoromethanesulphonic anhydride.

25


Compounds of formula (XX) may be prepared from compounds of formula (XXI):



(XXI)

5 where R²¹ and R³ are as defined above, by reaction of the compound (XXI) with azide, such as 4-toluenesulphonyl azide in the presence of a base such as N, N-diisopropylethylamine.


Compounds of formula (XXI) may be prepared from compounds of formula (XXII):



(XXII)

10 by reaction of the compound (XXII) with an alcohol R³OH, such as p-methoxybenzyl alcohol, for example under reflux.


Compounds of formula (XXII) may for example be prepared by hydrogenation, eg using Pd/C and hydrogen, of compounds of formula (XXIII):



(XXIII)

where R²¹ is as defined above and the amino group in the azetidinone ring may optionally be protected by a protecting group PG as described above, which may be removed as described above to yield the compound of formula (XXII).

20 Compounds of formula (XXIII) may be prepared from compounds of formula (IX) described above with reference to route A, by reaction with known (Oppi Briefs (1990), 22:1, p109-111, C. Bodurow *et al*) 2, 2-(dimethyl)-6-[(triphenylphosphoranylidene)methyl]-4H-1,3-dioxin-4-one:



Compounds of formula (II), (IV), (V), (VI), (VII), (VIII), (XII), (XIII), (XX), (XXI), (XXII) and (XXIII) are novel compounds and as such form part of the invention.

The present invention also provides a pharmaceutical composition which
 5 comprises a compound of formula (I) or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof and a pharmaceutically acceptable carrier. The compositions of the invention include those in a form adapted for oral, topical or parenteral use and may be used for the treatment of bacterial infection in mammals including humans.

10 The antibiotic compounds according to the invention may be formulated for administration in any convenient way for use in human or veterinary medicine, by analogy with other antibiotics.

The composition may be formulated for administration by any route, such as oral, topical or parenteral, especially oral. The compositions may be in the form of
 15 tablets, capsules, powders, granules, lozenges, creams or liquid preparations, such as oral or sterile parenteral solutions or suspensions.

The topical formulations of the present invention may be presented as, for instance, ointments, creams or lotions, eye ointments and eye or ear drops, impregnated dressings and aerosols, and may contain appropriate conventional
 20 additives such as preservatives, solvents to assist drug penetration and emollients in ointments and creams.

The formulations may also contain compatible conventional carriers, such as cream or ointment bases and ethanol or oleyl alcohol for lotions. Such carriers may be present as from about 1% up to about 98% of the formulation. More usually they
 25 will form up to about 80% of the formulation.

Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine;
 30 tableting lubricants, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants, for example potato starch; or acceptable wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in normal pharmaceutical practice. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or
 35 may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives,

such as suspending agents, for example sorbitol, methyl cellulose, glucose syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; 5 preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and, if desired, conventional flavouring or colouring agents.

Suppositories will contain conventional suppository bases, e.g. cocoa-butter or other glyceride.

10 For parenteral administration, fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, water being preferred. The compound, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions the compound can be dissolved in water for injection and filter sterilised before filling into a suitable vial or ampoule and sealing.


15 Advantageously, agents such as a local anaesthetic, preservative and buffering agents can be dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. The dry lyophilized powder is then sealed in the vial and an accompanying vial of water for injection may be supplied to reconstitute the liquid prior to use. Parenteral 20 suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilization cannot be accomplished by filtration. The compound can be sterilised by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the 25 compound.

The compositions may contain from 0.1% by weight, preferably from 10-60% by weight, of the active material, depending on the method of administration. Where the compositions comprise dosage units, each unit will preferably contain from 50-500 mg of the active ingredient. The dosage as employed for adult human 30 treatment will preferably range from 100 to 3000 mg per day, for instance 1500 mg per day depending on the route and frequency of administration. Such a dosage corresponds to 1.5 to 50 mg/kg per day. Suitably the dosage is from 5 to 20 mg/kg per day.

35 No unacceptable toxicological effects are expected when a compound of formula (Ia) or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof is administered in the above-mentioned dosage range.

The compound of formula (Ia) may be the sole therapeutic agent in the compositions of the invention or a combination with other antibiotics or with a β -lactamase inhibitor may be employed.

Advantageously, the compositions also comprise a compound of formula (XIII) or a pharmaceutically acceptable salt or ester thereof:




(XXIV)

5 wherein

A is hydroxyl, substituted hydroxyl, thiol, substituted thiol, amino, mono- or di-hydrocarbyl- substituted amino, or mono- or di-acylamino; an optionally substituted triazolyl group; or an optionally substituted tetrazolyl group as described in EP-A-0 053 893.

10 A further advantageous composition comprises a compound of formula (Ia) or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof together with a compound of formula (XXV) or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof:




15

(XXV)


wherein

B represents hydrogen, halogen or a group of formula:



20 in which R^x and R^y are the same or different and each represents hydrogen, (C₁₋₆) alkoxy carbonyl or carboxy, or a pharmaceutically acceptable salt thereof.

Further suitable β -lactamase inhibitors include 6-alkylidene penems of formula (XXVI):



25

(XXVI)

or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, wherein

R^m and R^n are the same or different and each represents hydrogen, or a (C₁₋₁₀) hydrocarbon or heterocyclic group optionally substituted with a functional group; and RP represents hydrogen or a group of formula R^I or $-SR^I$ where R^I is an optionally substituted (C₁₋₁₀) hydrocarbon or heterocyclic group, as described in EP-A-0
 5 041 768.

Further suitable β -lactamase inhibitors include 6 β -bromopenicillanic acid and pharmaceutically acceptable salts and *in vivo* hydrolysable esters thereof and 6 β -iodopenicillanic acid and pharmaceutically acceptable salts and *in vivo* hydrolysable esters thereof described in, for example, EP-A-0 410 768 and EP-A-0
 10 154 132 (both Beecham Group).

Such compositions of this invention which include a β -lactamase inhibitory amount of a β -lactamase inhibitor are formulated in a conventional manner using techniques and procedures *per se* known in the art.

The antibiotic compounds of the present invention are active against a wide
 15 range of organisms including both Gram-negative organisms such as *E.coli* and Gram-positive organisms such as *S.aureus*.

The following Examples illustrate the preparation of compounds of the invention and intermediates thereto.

20 EXAMPLE 1 (Route A)

Pivaloyloxymethyl (6R,7S)-7-[2-(2-aminothiazol-4-yl)-2-(Z)-methoxyimino-acetamido]-[(S)-tetrahydrofuran-2-yl]-1-carba-1-dethiaceph-3-em-4-carboxylate

25 a) (3S,4S)-4-[(R)-2,2-Dimethyl-1,3-dioxolon-4-yl]-1-(4-methoxyphenyl)-3-phthalimidoazetidin-2-one

A crude aqueous solution of L-(S)-glyceraldehyde acetonide (obtained from 0.15mol of 5,6-isopropylidene-L-gulonono-1,4-lactone, C. Hubschwerlen, Synthesis, 1986, 962) was treated with a solution of *p*-anisidine (16.2g, 0.13mol) in
 30 dichloromethane (300ml). The reaction mixture was stirred overnight at room temperature, then the organic phase separated and the aqueous phase extracted twice with dichloromethane (100ml). The combined organic layers were dried over magnesium sulphate, filtered and reduced in volume to ~200ml. The crude imine was treated with triethylamine (26.7ml, 0.19mol) and cooled to -30°C. A solution of
 35 phthalimidoacetyl chloride (42.8g, 0.19mol) in dichloromethane (150ml) was added dropwise over 45min. After stirring for 2.5h at room temperature, the reaction mixture was filtered, and the filtrate washed successively with water (x3), 1M hydrochloric acid, saturated aqueous sodium hydrogen carbonate solution, water and brine. The organic phase was dried over magnesium sulphate, filtered and

concentrated *in vacuo*. The residue was passed through a short column of silica eluting with dichloromethane, concentrated, and the residue purified by crystallisation from ethyl acetate/hexane. The *title compound* as obtained as a yellow solid (23.78g, 44%); m.p. 164 - 166°C; $[\alpha]_D +55.0^\circ$ (c 1.00 CHCl₃); (Found: C, 65.44; H, 5.27; N, 6.75%; M^+ 422.1487. C₂₃H₂₂N₂O₆ requires C, 65.40; H, 5.25; N, 6.63%; M 422.1478.); ν_{\max} (CH₂Cl₂) 1760, 1724, 1514, 1384, 1265 and 1247cm⁻¹; δ_H (CDCl₃) 1.27 (3H, s), 1.50 (3H, s), 3.53 (1H, dd, J 8.4, 6.5Hz), 3.75 (1H, dd, J 8.4, 6.5Hz), 3.82 (3H, s), 4.42 - 4.57 (2H, m), 5.53 (1H, d, J 5.4Hz), 6.91 (2H, d, J 9.1Hz), 7.74 (2H, d, J 9.1Hz), 7.70 - 7.84 (2H, m) and 7.89 - 7.95 (2H, m).

10

b) (3*S*,4*S*)-3 Amino-4-[(*R*)-2,2-dimethyl-1,3-dioxolan-4-yl]-1-(4-methoxyphenyl)azetidin-2-one

Methyl hydrazine (8.1ml, 152.3mmol) was added to a solution of (3*S*,4*S*)-4-[(*R*)-2,2-dimethyl-1,3-dioxolan-4-yl]-1-(4-methoxyphenyl)-3-phthalimidoazetidin-2-one (23.78g, 56.4mmol) in dichloromethane (230ml). The reaction mixture was heated at reflux for 6h and then stirred overnight at room temperature. The precipitated solid was filtered off through celite and the filtrate washed successively with saturated aqueous sodium hydrogen carbonate solution and brine. After drying over magnesium sulphate, the solvent was evaporated *in vacuo* to yield a pale yellow solid. Recrystallisation from dichloromethane/hexane yielded the *title compound* as a white solid (12.26g, 74%); m.p. 163-165°C; $[\alpha]_D -98.5^\circ$ (c 1.00 MeOH); (Found: M^+ 292.1428. C₁₅H₂₀N₂O₄ requires M 292.1423); ν_{\max} (CH₂Cl₂) 1744, 1513 and 1270cm⁻¹; δ_H (CDCl₃) 1.35 (3H, s), 1.43 (3H, s), 1.70 (2H, br.s, exch.), 3.79 (3H, s), 3.85 (1H, m), 4.20 (1H, m), 4.27-4.38 (3H, m), 6.86 (2H, d, J 9.0Hz) and 7.55 (2H, d, J 9.0Hz).

25

c) (3*S*,4*S*)-4-[(*R*)-2,2-Dimethyl-1,3-dioxolan-4-yl]-1-(4-methoxyphenyl)-3-phenylacetamidoazetidin-2-one

A solution of (3*S*,4*S*)-3-amino-4-[(*R*)-2,2-dimethyl-1,3-dioxolan-4-yl]-1-(4-methoxyphenyl)azetidin-2-one (12.21g, 41.8mmol) in dichloromethane (160ml) was cooled to 0°C and treated sequentially with phenylacetyl chloride (6.1ml, 46.1mmol), then triethylamine (6.4ml, 45.9mmol). After stirring at 0°C for 15min., the mixture was warmed to room temperature and stirred for a further 30min. The reaction mixture was diluted with dichloromethane and washed twice with water, then brine. The organic layer was dried over magnesium sulphate, filtered and the solvent evaporated *in vacuo* to yield a solid. Trituration with diethyl ether yielded the *title compound* (16.16g, 94%) as a white amorphous solid; $[\alpha]_D 0.0^\circ$ (c = 1.00 DMF); ν_{\max} (KBr) 1757, 1661 and 1510cm⁻¹; δ_H (CDCl₃) 1.16 (3H, s), 1.25 (3H, s), 3.62 (2H, s), 3.69-3.82 (2H, m), 3.76 (3H, s), 4.02 (1H, m), 4.36 (1H, dd, J 5.5, 4.0Hz),

35

5.58 (1H, dd, J 9.4, 5.5Hz), 6.56 (1H, d, J 9.4Hz), 6.83 (2H, d, J 8.9Hz) and 7.25-7.40 (7H, m); m/z (EI) 410 (5); (CI, +ve ion, ammonia) 411 (MH^+).

d) **(3S,4S)-4-Formyl-1-(4-methoxyphenyl)-3-phenylacetamidoazetidin-2-one**

5 Periodic acid (18.7g, 45.6mmol) was added to a suspension of (3S,4S)-4-[(*R*)-2,2-dimethyl-1,3-dioxolan-4-yl]-1-(4-methoxyphenyl)-3-phenylacetamidoazetidin-2-one (15.1g, 36.8mmol) in tetrahydrofuran (210ml) and water (210ml). The reaction mixture was heated under reflux for 1.5h and then cooled in ice. The precipitated product was collected by filtration, washed with water and dried over phosphorus pentoxide to yield the *title compound* as a mixture of aldehyde and the corresponding hydrate (10.18g, 82%); ν_{\max} (KBr) 1713, 1638, 1552 and 1514 cm^{-1} ; aldehyde δ_{H} (d_6 -DMSO) 3.43 and 3.50 (2H, ABq, J 14.4Hz), 3.73 (3H, s), 4.95 (1H, dd, J 6.1, 1.2Hz), 5.19 (1H, m), 6.95 (2H, d, J 9.0Hz), 7.18-7.35 (7H, m), 9.09 (1H, d, J 7.3Hz) and 9.52 (1H, d, J 1.2Hz); hydrate δ_{H} (d_6 -DMSO) 3.50 (2H, s), 3.72 (3H, s), 4.16 (1H, t, J 5.6Hz), 5.07 (1H, q, J 5.8Hz), 5.29 (1H, dd, J 9.4, 5.6Hz), 6.28 (2H, t, J 6.7Hz, exch.), 6.9 (2H, d, J 9.1Hz), 7.19-7.35 (5H, m), 7.52 (2H, J 9.1Hz) and 8.52 (1H, d, J 9.4Hz); m/z (EI) 338 (10); (CI, +ve ion, ammonia) 339 (MH^+), 356 (MNH_4^+).

20 e) **(*S*)-Tetrahydrofuran-2-ylcarbonylmethylenetriphenylphosphorane**

A solution of triphenylphosphine (13.6g, 51.9mmol) in toluene (50ml) was added to a solution of crude (*S*)-2-bromoacetyltetrahydrofuran [prepared from (*S*)-2-tetrahydrofuroic acid (6.0g, 51.7mmol)] in toluene (50ml) over 30min. The reaction mixture was stirred overnight and the solid collected by filtration and washed with diethyl ether. (*S*)-Tetrahydrofuran-2-ylcarbonylmethylenetriphenylphosphonium bromide was isolated as an off-white solid (14.5g, 62% from (*S*)-2-tetrahydrofuroic acid). The phosphonium salt (14.5g, 31.9mmol) was dissolved in water (250ml) and added dropwise to a solution of sodium carbonate (3.30g, 31.1mmol) in water (20ml). The reaction mixture was stirred for 3h, the product collected by filtration and washed with water. After drying over phosphorus pentoxide, the *title compound* was obtained as a pale yellow solid (10.35g, 87%); m.p. 169-172°C; $[\alpha]_{\text{D}} -18.3^\circ$ (c 1.00 CHCl_3); (Found: C, 77.07; H, 6.15. $\text{C}_{24}\text{H}_{23}\text{O}_2\text{P}$; requires C, 76.99; H, 6.19%); ν_{\max} (CHCl_3) 1523, 1438, 1404, 1108 and 1069 cm^{-1} ; δ_{H} (CDCl_3) 1.80-2.09 (3H, m), 2.21 (1H, m), 3.89 (1H, m), 4.04 (1H, m), 4.17 (1H, d, J 26.2Hz), 4.34 (1H, dd, J 7.8, 5.7Hz) and 7.41-7.70 (15H, m).

f) **(3S,4R)-1-(4-Methoxyphenyl)-4-[3-oxo-3-[(*S*)-tetrahydrofuran-2-yl]propenyl]-3-phenylacetamidoazetidin-2-one**

A suspension of (3S,4S)-4-formyl-1-(4-methoxyphenyl)-3-phenyl-

acetamidoazetidin-2-one (10.39g, 30.7mmol) in acetonitrile (250ml) was treated with (S)-tetrahydrofuran-2-ylcarbonylmethylenetriphenylphosphorane (11.50g, 30.7mmol) and stirred at room temperature for 2 days. The bulk of the product was collected by filtration and washed with acetonitrile. The remainder of the product was purified by chromatography on silica gel eluting with ethyl acetate yielding a further 1.66g. The *title compound* was isolated as a white solid (total 12.12g, 91%); m.p. 159-162°C; $[\alpha]_D -83.4^\circ$ (c=1 CHCl₃); (Found: C, 69.41; H, 6.28; N, 6.20%; M^+ , 434.1832. C₂₅H₂₆N₂O₅ requires: C, 69.11; H, 6.03; N, 6.45%; M 434.11842); ν_{\max} (CHCl₃) 3414, 1751, 1682, 1631, 1513 and 1250cm⁻¹; δ_H (CDCl₃) 1.75-1.92 (3H, m), 2.18 (1H, m), 3.57 (2H, s), 3.76 (3H, s), 3.70-3.90 (2H, m), 4.39 (1H, m), 4.88 (1H, t, J 5.4Hz), 5.49 (1H, dd, J 8.0, 5.4Hz), 6.20 (1H, d, J 8.0Hz), 6.60 (1H, d, J 16.1Hz), 6.78-6.85 (3H, m) and 7.18-7.38 (7H, m).

g) **(3S,4R)-1-(4-Methoxyphenyl)-4-[3-oxo-3-[(S)-tetrahydrofuran-2-yl]propyl]-3-phenylacetamidoazetidin-2-one**

A solution of (3S,4R)-1-(4-methoxyphenyl)-4-[3-oxo-3-[(S)-tetrahydrofuran-2-yl]propenyl]-3-phenylacetamidoazetidin-2-one (12.1g, 27.9mmol) in tetrahydrofuran (250ml) was hydrogenated over 10% palladium on carbon (1.0g) for 3h. After filtration through celite, the partially insoluble product was dissolved in dichloromethane and methanol (1:1) and re-filtered through celite to remove the catalyst. Concentration of the filtrate *in vacuo* provided the *title compound* as an amorphous white solid (11.5g, 95%); (Found: M^+ 436.1997. C₂₅H₂₇N₂O₅ requires M 436.1998); ν_{\max} (KBr) 3277, 1758, 1708, 1655, 1542, 1510 and 1246cm⁻¹; δ_H (CDCl₃) 1.43 (1H, m), 1.78-1.95 (3H, m), 2.10-2.50 (4H, m), 3.62 (2H, s), 3.75 (3H, s), 3.91 (2H, m), 4.17 (1H, m), 4.24 (1H, m), 5.29 (1H, dd, J 7.8, 5.0Hz), 6.73 (1H, d, J 7.8Hz, exch.), 6.81 (2H, d, J 9.0Hz) and 7.25-7.36 (7H, m).

h) **(3S,4R)-4-[3-Oxo-3-[(S)-tetrahydrofuran-2-yl]propyl]-3-phenylacetamidoazetidin-2-one**

A suspension of (3S,4R)-1-(4-methoxyphenyl)-4-[3-oxo-3-[(S)-tetrahydrofuran-2-yl]propyl]-3-phenylacetamidoazetidin-2-one (4.66g, 10.69mmol) in tetrahydrofuran (200ml) was treated with a solution of ceric ammonium nitrate (17.3g, 31.57mmol) in water (120ml) at 0°C. After stirring for 30min. at 0°C, the reaction mixture was diluted with ethyl acetate and the aqueous phase extracted four times with a mixture of tetrahydrofuran and ethyl acetate (2:1). The combined organic extracts were washed successively with 5% aqueous sodium hydrogen carbonate solution, 10% aqueous sodium sulphite solution (x2), 5% aqueous sodium hydrogen carbonate solution, water and then brine. After drying over magnesium sulphate, the solvent was evaporated *in vacuo* to yield the crude *title compound*

(2.16g, 61%); (Found: M^+ 330.1586. $C_{18}H_{22}N_2O_4$ requires M 330.1586); ν_{\max} (CH_2Cl_2) 3411, 1770, 1715, 1681 and $1512cm^{-1}$; δ_H ($CDCl_3$) 1.60-1.96 (5H, m), 2.17 (1H, m), 2.40-2.53 (2H, m), 3.60 (2H, s), 3.78 (1H, m), 3.90 (2H, m), 4.25 (1H, m), 5.22 (1H, dd, J 6.9, 4.9Hz), 6.39 (1H, br.s, exch.), 6.68 (1H, d, J 9.8Hz), and
 5 7.25-7.40 (5H, m).

i) **4-Methoxybenzyl (RS)-2-hydroxy-2-[(3S,4R)-4-[3-oxo-3-[(S)-tetrahydrofuran-2-yl]propyl]-3-phenylacetamidoazetidin-2-on-1-yl]acetate**
p-Methoxybenzyl glyoxylate (3.20g, 16.5mmol) in 1,2-dichloroethane (50ml)
 10 was heated at reflux for 1h. using Dean and Stark apparatus. The solution was cooled in ice and treated successively with (3S,4R)-4-[3-oxo-3-[(S)-tetrahydrofuran-2-yl]propyl]-3-phenylacetamidoazetidin-2-one (4.10g, 12.4mmol) and triethylamine (170 μ l, 1.22mmol). After stirring at 0°C for 30min., the reaction mixture was concentrated *in vacuo*. The residue was purified by chromatography on silica gel
 15 eluting with 50% ethyl acetate in hexane, then ethyl acetate to yield the *title compound* as a yellow foam (4.53g, 70%); ν_{\max} (CH_2Cl_2) 3420, 3226, 1769, 1743, 1681, 1613 and $1516cm^{-1}$; m/z (FAB, +ve ion, 3-nitrobenzyl alcohol/sodium acetate) 547 (MNa^+).

20 j) **4-Methoxybenzyl 2-[(3S,4R)-4-[3-oxo-3-[(S)-tetrahydrofuran-2-yl]propyl]-3-phenylacetamidoazetidin-2-on-1-yl]-2-tri-*n*-butylphosphoranylidene acetate**

A solution of thionyl chloride (1.0ml, 13.71mmol) in THF (95ml) was added to the hydroxy compound (4.72g, 9.01mmol) and 2,6-lutidine (1.6ml, 13.74mmol) in
 25 THF (50ml) at -20°C. After stirring for 1h the reaction mixture was filtered through a pad of celite, and the filtrate evaporated *in vacuo*. Toluene was added and re-evaporated to yield 4-methoxybenzyl (RS)-2-chloro-2-[(3S,4R)-4-[3-oxo-3-[(S)-tetrahydrofuran-2-yl]propyl]-3-phenylacetamidoazetidin-2-on-1-yl]acetate as an oil.

30 The crude chloro compound was dissolved in dioxan (30ml) and treated with tri-*n*-butylphosphine (4.9ml, 19.67mmol). After stirring for 30min. at room temperature, the reaction mixture was diluted with ethyl acetate and washed successively with dilute sodium hydrogen carbonate solution, water and brine. The organic solution was dried, concentrated and then chromatographed on silica gel eluting with 50, 80%
 35 ethyl acetate in hexane, then ethyl acetate to give the *title compound* as a foam (5.92g, 93%); ν_{\max} (CH_2Cl_2) 3418, 1751, 1677, 1612, 1514 and $1465cm^{-1}$; m/z (FAB, +ve ion, 3-nitrobenzyl alcohol/sodium acetate) 731 (MNa^+).

k) **4-Methoxybenzyl (6R,7S)-7-Phenylacetamido-3-[(S)-tetrahydrofuran-2-**

yl]-1-carba-1-dethiaceph-3-em-4-carboxylate

A solution of the phosphorane (5.90g, 8.33mmol) and benzoic acid (20mg) in toluene (100ml) was heated at reflux for 10h. The reaction mixture was cooled, concentrated and the residue purified by chromatography on silica gel eluting with 50, then 70% ethyl acetate in hexane yielding the *title compound* as a yellow foam (3.54g, 87%); $[\alpha]_D -40.6^\circ$ (c 1.0 CHCl₃); (Found: M^+ 490.2096. C₂₈H₃₀N₂O₆ requires M 490.2104); ν_{\max} (CHCl₃) 3416, 1766, 1716, 1677, 1613, 1516 and 1394cm⁻¹; δ_H (CDCl₃) 1.12 (1H, m), 1.50 (1H, m), 1.83-1.96 (3H, m), 2.18-2.43 (3H, m), 3.57 and 3.65 (2H, ABq, J 16.1Hz), 3.76-3.90 (3H, m), 3.79 (3H, s), 4.92 (1H, dd, J 8.9, 6.8Hz), 5.10 and 5.19 (2H, ABq, J 11.9Hz), 5.26 (1H, m), 5.86 (1H, d, J 6.8Hz), 6.88 (2H, d, J 8.7Hz) and 7.20-7.32 (7H, m).

l) 4-Methoxybenzyl (6R,7S)-7-amino-3-[(S)-tetrahydrofuran-2-yl]-1-carba-1-dethiaceph-3-em-4-carboxylate

A solution of 4-methoxybenzyl (6R,7S)-7-phenylacetamido-3-[(S)-tetrahydrofuran-2-yl]-1-carba-1-dethiaceph-3-em-4-carboxylate (3.53g, 7.20mmol) and *N*-methylmorpholine (1.6ml, 14.6mmol) in dichloromethane (100ml) was treated with phosphorus pentachloride (2.25g, 10.80mmol) in dichloromethane (56ml) at -25°C. The reaction was stirred at -10±5°C for 45min., then methanol (15ml) was added, and stirring continued for 45min. at room temperature. Water (32ml) was then added, and the mixture vigorously stirred for a further 1h. The dichloromethane was evaporated *in vacuo*, and the aqueous residue adjusted to pH7 with concentrated ammonia solution in the presence of ethyl acetate. The mixture was extracted twice with ethyl acetate, dried and concentrated *in vacuo*. The residue was purified by chromatography on silica gel eluting with ethyl acetate, then 5% methanol in ethyl acetate yielding the *title compound* as a pale yellow foam (1.53g, 57%); $[\alpha]_D -114.3$ (c 1.0 CHCl₃); ν_{\max} (CH₂Cl₂) 1760, 1717, 1614 and 1516cm⁻¹; δ_H (CDCl₃) 1.34-2.45 (10H, m, 2H exch.), 3.68-3.96 (3H, m), 3.80 (3H, s), 4.46 (1H, d, J 5.4Hz), 4.94 (1H, dd, J 8.9, 6.8Hz), 5.13 and 5.20 (2H, ABq, J 12.0Hz), 6.89 (2H, d, J 8.6Hz) and 7.36 (2H, d, J 8.6Hz); m/z (CI, +ve ion, ammonia) 373 (MH^+).

m) 4-Methoxybenzyl (6R,7S)-7-[2-(2-aminothiazol-4-yl)-2-(Z)-methoxyiminoacetamido]-3-[(S)-tetrahydrofuran-2-yl]-1-carba-1-dethiaceph-3-em-4-carboxylate

Methanesulphonyl chloride (350μl, 4.52mmol) was added to 2-(2-thiazol-4-yl)-2-(Z)-methoxyiminoacetic acid (909mg, 4.52mmol) and *N,N*-diisopropylethylamine (788μl, 4.52mmol) in DMF (15ml) at -30°C. After stirring at -30±10°C for 30min., a solution of 4-methoxybenzyl (6R,7S)-7-amino-3-[(S)-tetrahydrofuran-2-yl]-1-carba-1-dethiaceph-3-em-4-carboxylate (1.52g, 4.10mmol) in

DMF (6ml) was added, followed by pyridine (366 μ l, 4.52mmol). The reaction mixture was transferred to an ice-bath and stirring continued for a further 1h. After dilution with ethyl acetate, the solution was washed successively with saturated sodium hydrogen carbonate solution, 5% aqueous citric acid, water (x2) and brine, dried and then concentrated *in vacuo*. The residue was purified by chromatography on silica gel eluting with ethyl acetate to give the *title compound* as a pale yellow foam (1.82g, 80%); $[\alpha]_D +51.5$ (c 1.0 CHCl₃); ν_{\max} (CH₂Cl₂) 3478, 1755, 1718, 1675, 1614, 1531 and 1516cm⁻¹; δ_H (CDCl₃) 1.50-1.79 (2H, m), 1.84-1.97 (2H, m), 2.08-2.50 (4H, m), 3.81 (3H, s), 3.82-3.96 (3H, m), 3.98 (3H, s), 4.96 (1H, m), 5.17 (2H, s), 5.65 (1H, dd, *J* 7.9, 5.0Hz), 5.93 (2H, br.s, exch.), 6.72 (1H, s), 6.89 (2H, d, *J* 8.6Hz), 7.34 (2H, d, *J* 8.6Hz) and 8.48 (1H, br.s); *m/z* (FAB, +ve ion thioglycerol) 556 (*MH*⁺).

n) Sodium (6*R*,7*S*)-7-[2-(2-aminothiazol-4-yl)-2-(*Z*)-methoxyiminoacetamido]-3-[(*S*)-tetrahydrofuran-2-yl]-1-carba-1-dethiaceph-3-em-4-carboxylate

Aluminium chloride (58mg, 0.44mmol) was added to anisole (2.3ml) and dry dichloromethane (1.3ml) at -20°C and stirred for 15min. The temperature of the cooling bath was then lowered to -40°C before addition of 4-methoxybenzyl (6*R*,7*S*)-7-[2-(2-aminothiazol-4-yl)-2-(*Z*)-methoxy-iminoacetamido]-3-[(*S*)-tetrahydrofuran-2-yl]-1-carba-1-dethiaceph-3-em-4-carboxylate (80mg, 0.14mmol) in dichloromethane (5ml). After 10min., the solution was treated with trisodium citrate (0.5M, 4.5ml) and then vigorously stirred for 10min. at room temperature. The aqueous phase was separated, washed twice with dichloromethane and concentrated *in vacuo*. The residue was chromatographed on HP20SS eluting with water, 1%, then 2% THF in water. Fractions containing the product (h.p.l.c. analysis) were combined, concentrated and freeze-dried to give the *title compound* (42mg, 66%); ν_{\max} (KBr) 1745, 1659, 1594, 1531 and 1386cm⁻¹; δ_H (d₆-DMSO) 1.42-1.56 (2H, m), 1.72-1.90 (3H, m), 2.02-2.16 (3H, m), 3.55-3.80 (3H, m), 3.83 (3H, s), 4.95 (1H, m), 5.23 (1H, dd, *J* 8.6, 4.9Hz), 6.73 (1H, s), 7.22 (2H, br.s, exch.) and 9.19 (1H, d, *J* 8.6Hz); *m/z* (FAB, +ve ion, thioglycerol) 458 (*MH*⁺).

o) Pivaloyloxymethyl (6*R*,7*S*)-7-[2-(2-aminothiazol-4-yl)-2-(*Z*)-methoxyiminoacetamido]-3-[(*S*)-tetrahydrofuran-2-yl]-1-carba-1-dethiaceph-3-em-4-carboxylate

Pivaloyloxymethyl bromide (343mg, 1.76mmol) in *N*-methylpyrrolidin-2-one (4ml) was added dropwise over 1h to a solution of sodium (6*R*,7*S*)-7-[2-(2-aminothiazol-4-yl)-2-(*Z*)-methoxyiminoacetamido]-3-[(*S*)-tetrahydro-furan-2-yl]-1-carba-1-dethiaceph-3-em-4-carboxylate (200mg, 0.44mmol) in *N*-methylpyrrolidin-2-

one (10ml) containing finely powdered potassium carbonate (121mg, 0.95mmol). After stirring for 30min., the mixture was diluted with ethyl acetate, washed twice with water and brine, dried and concentrated. The residue was purified by chromatography on silica gel eluting with 50% ethyl acetate in hexane, then ethyl acetate to give the *title compound* as a colourless foam (115mg, 48%); $[\alpha]_D +65.4^\circ$ (c 1.0 CHCl₃); (Found: M^+ 549.1911. C₂₄H₃₁N₅O₈S requires 549.1893); ν_{\max} (CH₂Cl₂) 3486, 1758, 1674, 1622, 1531 and 1387cm⁻¹; δ_H (CDCl₃) 1.23 (9H, s), 1.50-1.72 (2H, m), 1.92-2.52 (6H, m), 3.71-3.90 (3H, m), 4.00 (3H, s), 4.93 (1H, dd, J 8.8, 6.9Hz), 5.64 (1H, dd, J 7.7, 5.0Hz), 5.66 and 5.82 (2H, ABq, J 5.6Hz), 6.02 (2H, br.s, exch.), 6.77 (1H, s), and 8.29 (1H, d, J 7.7Hz).

EXAMPLE 2 Route 2

4-Methoxybenzyl (6*R*,7*S*)-7-phenylacetamido-3-[(*R* and *S*)-tetrahydrofuran-2-yl]-1-carb-1-dethiaceph-3-em-4-carboxylate

a) (3*S*,4*R*)-4-[(2,2-Dimethyl-4*H*-1,3-dioxin-4-on-6-yl)ethenyl]-1-(4-methoxyphenyl)-3-phenylacetamidoazetidin-2-one

A suspension of (3*S*,4*S*)-4-formyl-1-(4-methoxyphenyl)-3-phenylacetamidoazetidin-2-one (10.18g, 30.1mmol) in acetonitrile (450ml) was treated with 2,2-(dimethyl)-6-[(triphenylphosphoranylidene)methyl]-4*H*-1,3-dioxin-4-one (12.5g, 31.1mmol) and stirred at room temperature for 3 days. The reaction mixture was concentrated *in vacuo* and the residue purified by flash chromatography on silica gel eluting with ethyl acetate to yield the *title compound* as a yellow foam (12.40g, 89%); $[\alpha]_D -127.5^\circ$ (c 1.0 CHCl₃); ν_{\max} (CH₂Cl₂) 3416, 1756, 1724, 1683 and 1513cm⁻¹; δ_H (CDCl₃) 1.72 (3H, s), 1.73 (3H, s), 3.59 (2H, s), 3.77 (3H, s), 4.88 (1H, dd, J 6.0, 5.4Hz), 5.27 (1H, s), 5.44 (1H, dd, J 7.8, 5.4Hz), 6.02 (1H, d, J 15.8Hz), 6.17 (1H, d, J 7.8Hz), 6.42 (1H, dd, J 15.8, 6.1Hz), 6.83 (2H, d, J 9.0Hz) and 7.17-7.33 (7H, m); m/z (FAB, +ve ion, 3-nitrobenzyl alcohol/ sodium acetate) 485(MNa^+).

b) (3*S*,4*R*)-4-[(2,2-Dimethyl-4*H*-1,3-dioxin-4-on-6-yl)ethyl]-1-(4-methoxyphenyl)-3-phenylacetamidoazetidin-2-one

A solution of (3*S*,4*R*)-4-[(2,2-dimethyl)-4*H*-1,3-dioxin-4-on-6-yl)ethenyl]-1-(4-methoxyphenyl)-3-phenylacetamidoazetidin-2-one (12.4g, 26.8mmol) in tetrahydrofuran (250ml) was hydrogenated over 10% palladium on carbon (1.2g) for 3h. After filtration through a pad of celite, the filtrate was concentrated to yield the *title compound* (12.07g, 97%); ν_{\max} (CH₂Cl₂) 3416, 1747, 1726, 1684 and 1514cm⁻¹; δ_H (CDCl₃) 1.67 (3H, s), 1.68 (3H, s), 2.02-2.15 (4H, m), 3.63 (2H, s), 3.77 (3H, s), 4.21 (1H, m), 5.13 (1H, s), 5.35 (1H, dd, J 7.6, 5.0Hz), 6.77 (1H, d, J 7.6Hz), 6.81

(2H, d, J 9.0Hz), 7.19 (2H, d, J 9.0Hz) and 7.23-7.40 (5H, m); m/z (FAB, +ve ion, 3-nitrobenzyl alcohol/sodium acetate) 487 (MNa^+).

c) (3*S*,4*R*)-4-[(2,2-Dimethyl)-4H-1,3-dioxin-4-on-6-yl)ethyl]-3-phenylacetamidoazetidin-2-one

A suspension of (3*S*,4*R*)-4-[(2,2-dimethyl-4H-1,3-dioxin-4-on-6-yl)ethyl]-1-(4-methoxyphenyl)-3-phenylacetamidoazetidin-2-one (10.58g, 22.80mmol) in tetrahydrofuran (425ml) was treated with a solution of ceric ammonium nitrate (40.0g, 73.0mmol) in water (245ml) at 0°C. After stirring for 10min. at 0°C, the reaction mixture was diluted with ethyl acetate and the aqueous phase extracted four times with a mixture of tetrahydrofuran and ethyl acetate (2:1). The combined organic extracts were washed successively with 5% aqueous sodium hydrogen carbonate solution, 10% aqueous sodium sulphite solution (x3), 5% aqueous sodium hydrogen carbonate solution, water and then brine. After drying over magnesium sulphate, the solvent was evaporated *in vacuo* to yield the crude *title compound* (7.50g, 92%); ν_{\max} (CH_2Cl_2) 3410, 1771, 1725, 1684, 1636 and 1512 cm^{-1} ; δ_H ($CDCl_3$) 1.62-1.75 (2H, m), 1.65 (6H, s), 2.12-2.21 (2H, m), 3.95 (2H, s), 3.80 (1H, m), 5.05 (1H, br.s, exch.), 5.25 (1H, m), 5.29 (1H, s), 6.78 (1H, d, J 7.9Hz) and 7.21-7.38 (5H, m); m/z (FAB, -ve ion, thioglycerol) 357 ($M-H$)⁻.

d) 4-Methoxybenzyl 3-oxo-5-[(3*S*,4*R*)-3-phenylacetamidoazetidin-2-on-4-yl]pentanoate

A solution of 4-methoxybenzyl alcohol (1.50g, 10.87mmol) in toluene (6ml) was added to a solution of (3*S*,4*R*)-4-[(2,2-dimethyl-4H-1,3-dioxin-4-on-6-yl)ethyl]-3-phenylacetamidoazetidin-2-one (3.86g, 10.78mmol) and heated to reflux for 1.5h. The reaction mixture was concentrated *in vacuo* and the residue triturated with toluene to give the *title compound* (3.50g, 75%) as a crude product; ν_{\max} (CH_2Cl_2) 3412, 1772, 1747, 1717, 1684 and 1514 cm^{-1} ; δ_H ($CDCl_3$) 1.63 (2H, m), 2.39 (2H, t, J 7.0Hz), 3.37 (2H, s), 3.58 (2H, s), 3.68 (1H, m), 3.81 (3H, s), 5.09 (2H, s), 5.18 (1H, m), 6.26 (1H, br.s, exch.), 6.63 (1H, d, J 7.9Hz), 6.89 (2H, d, J 8.6Hz) and 7.21-7.38 (7H, m); m/z (FAB, -ve ion, thioglycerol) 437 ($M-H$)⁻.

e) 4-Methoxybenzyl 2-diaza-3-oxo-5-[(3*S*,4*R*)-3-phenylacetamidoazetidin-2-on-4-yl]pentanoate

A solution of 4-methoxybenzyl 3-oxo-5-[(3*S*,4*R*)-3-phenylacetamidoazetidin-2-on-4-yl]pentanoate (3.50g, 8.0mmol) in acetonitrile (150ml) was treated with 4-toluenesulphonyl azide (2.21g, 11.22mmol) and *N,N*-diisopropylethylamine (2.1ml, 12.08mmol) at 0°C. After 10min., the ice-bath was removed and stirring was

continued at room temperature for 2h. The reaction mixture was diluted with ethyl acetate and washed with brine. After drying over magnesium sulphate, the solvent was evaporated *in vacuo* and the residue purified by chromatography on silica gel eluting with 50% ethyl acetate in hexane, then ethyl acetate to yield the *title*

- 5 *compound* (2.94g, 79%); $[\alpha]_D +33.6^\circ$ (c 1.0 CHCl_3); ν_{max} (CH_2Cl_2) 3410, 2142, 1770, 1713, 1683 and 1515cm^{-1} ; δ_{H} (CDCl_3) 1.59-1.78 (2H, m), 2.67-2.92 (2H, m), 3.57 and 3.64 (2H, ABq, J 15.6Hz), 3.78 (1H, m), 3.81 (3H, s), 5.18 (2H, s), 5.24 (1H, m), 6.37 (1H, br.s, exch.), 6.59 (1H, d, J 8.2Hz), 6.91 (2H, d, J 8.7Hz), and 7.23-7.36 (7H, m); m/z (CI, +ve ion, ammonia) 465 (MH^+).

10

f) **4-Methoxybenzyl (6*R*,7*S*)-7-phenylacetamido-3-(trifluoromethylsulphonyloxy)-1-carba-1-dethiaceph-3-em-4-carboxylate**

- A solution of 4-methoxybenzyl 2-diazo-3-oxo-5-[(3*S*,4*R*)-3-phenylacetamidoazetidin-2-on-4-yl]pentanoate (2.90g, 6.25mmol) in chloroform (75ml) was
15 heated to reflux in the presence of a catalytic quantity of rhodium (II) acetate dimer. After heating for 1h, the reaction mixture was cooled to 0°C and treated sequentially with *N,N*-diisopropylethylamine (2.2ml, 12.51mmol) and trifluoromethanesulphonic anhydride (1.16ml, 6.90mmol). After stirring for 30min. at 0°C , the mixture was concentrated *in vacuo*. The residue was purified by chromatography on silica gel
20 eluting with 30, then 50% ethyl acetate in hexane yielding the *title compound* as an orange foam (1.80g, 51%); $[\alpha]_D +24.1^\circ$ (c 1.0 CHCl_3); ν_{max} (CH_2Cl_2) 3416, 1783, 1734, 1685 and 1516cm^{-1} ; δ_{H} (CDCl_3) 1.45 (1H, m), 1.98 (1H, m), 2.56 (2H, m), 3.60 (2H, s), 3.79 (3H, s), 3.87 (1H, m), 5.13-5.32 (3H, m), 6.06 (1H, d, J 6.3Hz), 6.86 (2H, d, J 8.7Hz) and 7.21-7.40 (7H, m); m/z (CI, +ve ion, ammonia) 586
25 (MNH_4^+).

g) **4-Methoxybenzyl (6*R*,7*S*)-7-phenylacetamido-3-[(*S*)-tetrahydrofuran-2-yl]-1-carba-1-dethiaceph-3-em-4-carboxylate**

- A solution of (tetrahydrofuran-2-yl)tri-*n*-butylstannane (J.S. Sawyer, A.
30 Kucerovy, T.L. MacDonald and G.J. McGarvey, *J. Amer. Chem. Soc.*, 1988, 110, 842) (1.89g, 5.24mmol) in THF (10ml) was cooled to -78°C . *n*-Butyl lithium (3.53ml of a 1.48M solution in hexane, 5.22mmol) was then added and the solution was stirred for 15min. at -78°C . A second flask containing copper (I)
bromide.dimethylsulphide complex (538mg, 2.62mmol) suspended in a mixture of
35 dimethyl sulphide (8ml) and THF (16ml) was then cooled to -78°C . The α -lithiotetrahydrofuran species was transferred *via* a cannula to the suspension of copper bromide at -78°C . The red-brown homogeneous solution was stirred for 30min. at -78°C . A third flask containing a solution of 4-methoxybenzyl (6*R*,7*S*)-7-phenylacetamido-3-(trifluoromethylsulphonyloxy)-1-carba-1-dethiaceph-3-em-4-

carboxylate (900mg, 1.58mmol) in THF (12ml) was then cooled to -78°C. The cuprate species was transferred *via* a cannula to the solution of triflate at -78°C. The reaction mixture was stirred for 1.5h at -78°C, then quenched by the addition of saturated aqueous ammonium chloride (16ml). The resulting mixture was allowed to warm to room temperature then diluted with water and extracted twice with ethyl acetate. The combined organic phases were washed with water, brine, then dried over magnesium sulphate. After removal of the solvents *in vacuo*, the residue was purified by chromatography on silica gel eluting with 10, 20 and 30% ethyl acetate in dichloromethane. The title compound was obtained as a mixture of diastereoisomers (300mg, 39%); ν_{\max} (CH₂Cl₂) 3418, 1769, 1718, 1684 and 1516cm⁻¹; δ_{H} (CDCl₃) 1.10-2.68 (8H, m), 3.61 (2H, s), 3.72-3.91 (3H, m), 3.79 (3H, s), 4.93 and 5.09 (together 1H, 2m), 3.79 (3H, s), 4.93 and 5.09 (together 1H, 2m), 5.13-5.28 (3H, m), 5.93 and 5.98 (together 1H, 2d, *J* 7.9Hz), 6.87 (2H, d, *J* 8.6Hz) and 7.22-7.39 (7H, m); *m/z* (CI, +ve ion, ammonia) 491 (MH⁺).

15

EXAMPLE 3 Route A

4-Methoxybenzyl (6*R*,7*S*)-7-phthalimido-3-[(*S*)-tetrahydrofuran-2-yl]-1-carba-1-dethiaceph-3-em-4-carboxylate

20

a) (3*S*,4*S*)-4-Formyl-1-(4-methoxyphenyl)-3-phthalimidoazetidin-2-one

Aqueous 50% w/w periodic acid (6.3ml, 22mmol) was added to (3*S*,4*S*)-4-[(4*R*)-2,2-dimethyl-1,3-dioxolan-4-yl]-1-(4-methoxyphenyl)-3-phthalimido-azetidin-2-one (4.22g, 10mmol) in 50% aqueous THF (75ml) and heated under reflux for 2.5h. The cooled solution was extracted twice with ethyl acetate and the combined extracts washed twice with water then with brine, dried and evaporated to give a colourless solid. The solid was triturated with ether and the *title compound* filtered off and dried *in vacuo* (3.151g, 90%); $[\alpha]_{\text{D}} -214.3^{\circ}$ (*c* = 1.00 CHCl₃); ν_{\max} (CHCl₃) 1785 (sh), 1769, 1727, 1514, 1391, 1250, and 1124cm⁻¹; δ_{H} (CDCl₃) 3.73 (3H, s), 4.77 (1H, dd, *J* 6.29, 2.78Hz), 5.80 (1H, d, *J* 5.80Hz), 6.95 and 7.39 (4H, ABq, *J* 8.97Hz), 7.7 - 8.0 (4H, m) and 9.90 (1H, d, *J* 2.73Hz); *m/z* (EI) 350 (14), 149 (100%).

25

b) (3*S*,4*R*)-1-(4-Methoxyphenyl)-4-[3-oxo-4-[(*S*)-tetrahydrofuran-2-yl]-propenyl]-3-phthalimidoazetidin-2-one

35

(3*S*,4*S*)-4-Formyl-1-(4-methoxyphenyl)-3-phthalimidoazetidin-2-one (3.309g, 9.45mmol) and (*S*)-tetrahydrofuran-2-ylcarbonylmethylene-phosphorane (4.193g, 11mmol) in acetonitrile (100ml) were stirred for 48h then heated under reflux for 1.5h. The mixture was concentrated and flash chromatographed on silica gel eluting

with 50 - 60% ethyl acetate in hexane to give the product contaminated with triphenylphosphine oxide. Flash chromatography on silica gel eluting with ethyl acetate gave the *title compound* as a foam (3.646g, 87%); $[\alpha]_D -55.0^\circ$ ($c = 1.00$ CHCl_3); (Found: M^+ 446.1481. $\text{C}_{25}\text{H}_{22}\text{N}_2\text{O}_6$ requires M 446.1478); ν_{max} (CHCl_3) 1785, 1760, 1726, 1514, 1386 and 1249cm^{-1} ; δ_{H} (CDCl_3) 1.5 - 2.2 (4H, m), 3.65 - 3.85 (2H, m), 3.81 (3H, s), 4.39 (1H, dd, J 8.32, 5.93Hz), 5.03 (1H, t, J 6.09Hz), 5.70 (1H, d, J 5.63Hz), 6.63 (1H, d, J 16.18Hz), 6.85 - 7.0 (3H, m), 7.38 (2H, d, J 9.00Hz) and 7.7 - 7.9 (4H, m); m/z (FAB, +ve ion, thioglycerol) 447 (MH^+).

10 c) (3*S*,4*R*)-1-(4-Methoxyphenyl)-4-[3-oxo-4-[(*S*)-tetrahydrofuran-2-yl]propyl]-3-phthalimidoazetidin-2-one

(3*S*,4*R*)-1-(4-Methoxyphenyl)-4-[3-oxo-4-[(*S*)-tetrahydrofuran-2-yl]propenyl]-3-phthalimidoazetidin-2-one (3.646g) in THF (50ml) was hydrogenated in the presence of 10% palladium on carbon (200mg) until hydrogen uptake ceased, required ~2h. The catalyst was filtered off and the filtrate concentrated *in vacuo* then flash chromatographed on silica gel eluting with 50 - 70% ethyl acetate in hexane to give the *title compound* (3.036g, 83%); $[\alpha]_D +48.7^\circ$ ($c = 1.00$ CHCl_3); (Found: M^+ 448.1628. $\text{C}_{25}\text{H}_{24}\text{N}_2\text{O}_6$ requires M 448.1634); ν_{max} (CHCl_3) 1785, 1753, 1724, 1514, 1386, 1248 and 1220cm^{-1} ; δ_{H} (CDCl_3) 1.7 - 2.55 (8H, m), 3.7 - 3.85 (2H, m), 3.82 (3H, m), 4.15 - 4.25 (1H, m), 4.3 - 4.45 (1H, m), 5.47 (1H, d, J 5.18Hz), 6.94 and 7.51 (4H, ABq, J 8.92Hz) and 7.7 - 8.0 (4H, m); m/z (CI, +ve ion, ammonia) 449 (MH^+), 466 (MNH_4^+).

25 d) (3*S*,4*R*)-4-[3-Oxo-4-[(*S*)-tetrahydrofuran-2-yl]propyl]-3-phthalimidoazetidin-2-one

Ceric ammonium nitrate (11.141g, 20.3mmol) in water (60ml) was added dropwise to (3*S*,4*R*)-1-(4-methoxyphenyl)-4-[3-oxo-4-[(*S*)-tetrahydrofuran-2-yl]propyl]-3-phthalimidoazetidin-2-one (3.036g, 6.8mmol) in THF (100ml) cooled in an ice-salt bath. TLC after ~40ml of the ceric ammonium nitrate solution had been added showed no starting material so the addition was stopped, the reaction stirred 0.25h then ethyl acetate (20ml) added and the organic layer collected. The aqueous solution was extracted twice with ethyl acetate (50ml) then the combined ethyl acetate solutions washed successively with 5% sodium bicarbonate, 10% sodium sulphite twice, 5% sodium bicarbonate and brine, dried and evaporated to give the *title compound* as a foam (2.234g, 88%); $[\alpha]_D +6.3^\circ$ ($c = 1.00$ CHCl_3); ν_{max} (CHCl_3) 1794, 1769, 1727, 1512, 1389 and 1219cm^{-1} ; δ_{H} (CDCl_3) 1.7 - 2.2 (6H, m), 2.4 - 2.8 (2H, m), 3.7 - 4.0 (3H, m), 4.2 - 4.3 (1H, m), 5.41 (1H, d, J 5.07Hz), 6.54 (1H, s) and 7.7 - 7.95 (4H, m); m/z (CI, +ve ion, ammonia) 343 (MH^+), 360 (MNH_4^+).

e) **4-Methoxybenzyl (*RS*)-2-hydroxy-2-[(3*S*,4*R*)-4-[(*S*)-tetrahydrofuran-2-yl]propyl]-3-phthalimidoazetidin-2-on-1-yl]acetate**

4-Methoxybenzyl glyoxylate hydrate (1.647g, 8.5mmol) in 1,2-dichloroethane (40ml) was heated under a Dean and Stark trap for heavy entrainers containing 4A
 5 molecular sieves for 0.75h. The solution was allowed to cool then (3*S*,4*R*)-4-[3-oxo-4-[(*S*)-tetrahydrofuran-2-yl]propyl]-3-phthalimidoazetidin-2-one (2.234g, 6.5mmol) in dichloromethane (20ml) followed by triethylamine (90μl, 0.65mmol) were added. The reaction was stirred 0.5h then concentrated and flash chromatographed on silica gel eluting with 30 - 90% ethyl acetate in hexane to give the *title compound* (2.592g,
 10 74%); $[\alpha]_D +28.4^\circ$ ($c = 1.00$ CHCl₃); ν_{\max} (CHCl₃) 3685, 3518, 1772, 1725, 1516, 1385 and 1087cm⁻¹; m/z (CI, +ve ion, ammonia) 554 (MNH_4^+); (FAB, +ve ion, 3-nitrobenzyl alcohol/sodium acetate) 559 (MNa^+).

f) **4-Methoxybenzyl 2-[(3*S*,4*R*)-4-[3-oxo-3-[(*S*)-tetrahydrofuran-2-yl]propyl]-3-phthalimidoazetidin-2-on-1-yl]-2-tri-*n*-butylphosphoranylidenacetate**

A solution of thionyl chloride (530μl, 7.27mmol) in THF (3ml) was added to 4-methoxybenzyl (*RS*)-2-hydroxy-2-[(3*S*,4*R*)-4-[3-oxo-3-[(*S*)-tetrahydrofuran-2-yl]propyl]-3-phthalimidoazetidin-2-on-1-yl]acetate (2.59g, 4.84mmol) and 2,6-
 20 lutidine (850μl, 7.30mmol) in THF (50ml) at -20°C. After stirring for 1h, the reaction mixture was filtered through a pad of celite, and the filtrate evaporated *in vacuo*. Toluene was added and re-evaporated to yield 4-methoxybenzyl (*RS*)-2-chloro-2-[(3*S*,4*R*)-4-[3-oxo-3-[(*S*)-tetrahydrofuran-2-yl]propyl]-3-phthalimidoazetidin-2-on-1-yl]acetate.

25 The crude chloro compound was dissolved in dioxan (20ml) and treated with tri-*n*-butylphosphine (2.65ml, 10.63mmol). After stirring for 30min. at room temperature, the reaction mixture was diluted with ethyl acetate and washed successively with hydrochloric acid (0.5M), dilute sodium hydrogen carbonate solution, water and brine. The organic solution was dried, concentrated and then
 30 chromatographed on silica gel eluting with 30, 50 and 70% ethyl acetate in hexane to give the *title compound* as a yellow oil (2.90g, 83%); (Found: M^+ 720.3553. C₄₀H₅₃N₂O₈P requires M 720.3540); ν_{\max} (CH₂Cl₂) 1755, 1721, 1613, 1514 and 1387cm⁻¹.

g) **4-Methoxybenzyl (6*R*,7*S*)-7-Phthalimido-3-[(*S*)-tetrahydrofuran-2-yl]-1-carba-1-dethiaceph-3-em-4-carboxylate**

A solution of 4-methoxybenzyl 2-[(3*S*,4*R*)-4-[3-oxo-3-[(*S*)-tetrahydrofuran-2-yl]propyl]-3-phthalimidoazetidin-2-on-1-yl]-2-tri-*n*-butylphosphoranylidenacetate (2.90g, 4.03mmol) and benzoic acid 920mg in toluene (50ml) was heated to reflux

- for 10h. The reaction mixture was cooled, concentrated and the residue purified by chromatography on silica gel eluting with 30, then 50% ethyl acetate in hexane yielding the *title compound* as a colourless foam (1.77g, 88%); $[\alpha]_D -76.6^\circ$ (c 1.0 CHCl_3); (Found: M^+ 502.1734. $\text{C}_{28}\text{H}_{26}\text{N}_2\text{O}_7$ requires M 502.1740); ν_{max} (CH_2Cl_2) 1772, 1724, 1613, 1516 and 1386cm^{-1} ; δ_{H} (CDCl_3) 1.60 (1H, m), 1.86-1.99 (4H, m), 2.28-2.42 (3H, m), 3.80 (3H, s), 3.82-3.95 (3H, m), 5.00 (1H, dd, J 8.9, 6.9Hz), 5.17 and 5.24 (2H, ABq, J 11.9Hz), 5.59 (1H, d, J 5.1Hz), 6.88 (2H, d, J 8.7Hz), 7.39 (2H, d, J 8.7Hz), 7.75-7.80 (2H, m) and 7.84-7.89 (2H, m).

10 Example 4

Sodium (6*R*,7*S*)-7-[2-(2-aminothiazol-4-yl)-2-(*Z*)-prop-2-yloxyimino- acetamido]-3-[(2*S*)-tetrahydrofuran-2-yl]-1-carba-1-dethiaceph-3-em-4- carboxylate

- 15 a) 4-Methoxybenzyl (6*R*,7*S*)-7-[2-(2-aminothiazol-4-yl)-2-(*Z*)-prop-2-yloxyiminoacetamido]-3-[(2*S*)-tetrahydrofuran-2-yl]-1-carba-1-dethiaceph-3-em-4-carboxylate
- 2-[(2-Aminothiazol-4-yl)-2-(*Z*)-prop-2-yloxyiminoacetic acid (52mg, 2.27mmol) in DMF (2ml) was treated with methanesulphonyl chloride (17 μl , 2.20mmol) and *N*-*N*-diisopropylethylamine (39 μl , 2.24mmol) as described in Example 1(m). This was then treated successively with a solution of 4-methoxybenzyl (6*R*, 7*S*)-7-amino-3-[(2*S*)-tetrahydrofuran-2-yl]-1-carba-1-dethiaceph-3-em-4-carboxylate (70mg, 1.88mmol) in DMF (2ml) and pyridine (18 μl , 2.23mmol). After work-up the product was purified by chromatography on silica gel eluting with 50, 70 and 100% ethyl acetate in hexane to yield the *title compound* as a colourless foam (85mg, 78%); ν_{max} (CH_2Cl_2) 3482, 1768, 1718, 1680, 1608, 1516 and 1390cm^{-1} ; δ_{H} (CDCl_3) 1.26 (3H, d, J 6.2Hz), 1.29 (3H, d, J 6.2Hz), 1.42-2.55 (8H, m), 3.81 (3H, s), 3.82-3.98 (3H, m), 4.56 (1H, sept, J 6.2Hz), 4.97 (1H, dd, J 8.9, 6.8Hz), 5.18 (2H, s), 5.28 (2H, br.s, exch.), 5.43 (1H, dd, J 6.7, 4.9Hz), 6.88 (2H, d, J 8.6Hz), 6.89 (1H, s), 7.02 (1H, br.d, J 6.7Hz) and 7.35 (2H, d, J 8.6Hz); m/z (CI, +ve ion, ammonia) 584 ($M\text{H}^+$).

- b) Sodium (6*R*,7*S*)-7-[2-(2-aminothiazol-4-yl)-2-(*Z*)-prop-2-yloxyimino-acetamido]-3-[(2*S*)-tetrahydrofuran-2-yl]-1-carba-1-dethiaceph-3-em-4-carboxylate

A solution of 4-methoxybenzyl (6*R*,7*S*)-7-[2-(2-aminothiazol-4-yl)-2-(*Z*)-prop-2-yloxyiminoacetamido]-3-[(2*S*)-tetrahydrofuran-2-yl]-1-carba-1- dethiaceph-3-em-4-carboxylate (85mg; 0.15mmol) in dichloromethane (5ml) was added to a solution of aluminium chloride (58mg, 0.44mmol) in anisole (2.4ml) and

dichloromethane (1.3ml) as described in Example 1 (n). After quenching with trisodium citrate (0.5M, 4.5ml) and subsequent work-up, the product was purified by chromatography on HP20SS eluting with water, then 1,2,4 and 5% THF in water. Fractions containing the product (h.p.l.c. analysis) were combined and freeze-dried to give the *title compound* (35mg, 49%); ν_{\max} (KBr) 1745, 1659, 1594, 1532 and 1385 cm^{-1} ; δ_{H} (d_6 -DMSO) 1.18 (3H, d, J 6.2Hz), 1.20 (3H, d, J 6.2Hz), 1.41-1.60 (2H, m), 1.75-1.88 (3H, m), 2.01-2.14 (3H, m), 3.53-3.80 (3H, m), 4.29 (1H, sept, J 6.2Hz), 4.92 (1H, dd, J 8.7, 6.8Hz), 5.20 (1H, dd, J 8.4, 4.9Hz), 6.70 (1H, s), 7.23 (2H, br.s, exch.) and 9.15 (1H, d, J 8.4Hz); m/z (FAB, +ve ion, thioglycerol) 486 (MH⁺).

Example 5

Sodium (6*R*,7*S*)-7-[2-(2-aminothiazol-4-yl)-2-(*Z*)-hydroxyimino- acetamido]-3-[(2*S*)-tetrahydrofuran-2-yl]-1-carba-1-dethiaceph-3-em-4- carboxylate

a) 4-Methoxybenzyl (6*R*,7*S*)-7-[2-(2-Tritylaminothiazol-4-yl)-2-[(*Z*)-2-methoxyprop-2-yloxyimino]acetamido]-3-[(2*S*)-tetrahydrofuran-2-yl]-1-carba-1-dethiaceph-3-em-4-carboxylate

2-Methoxypropene (93 μl , 0.97mmol) was added to a suspension of (*Z*)-2-hydroxyimino-2-(2-tritylamino-4-thiazol)acetic acid (138mg, 0.32mmol) in dichloromethane (3ml) at 10°C. The mixture was stirred for 30 min at room temperature and then concentrated to give 2-(2-tritylaminothiazol- 4-yl)-2-[(*Z*)-2-methoxyprop-2-yloxyimino]acetic acid.

The crude acid in DMF (2ml) was treated with methanesulphonyl chloride (25 μl , 0.32mmol) and *N,N*-diisopropylethylamine (56 μl , 0.32mmol) as described in Example 1(m). This was then treated successively with a solution of 4-methoxybenzyl (6*R*,7*S*)-7-amino-3-[(2*S*)-tetrahydrofuran-2- yl]-1-carba-1-dethiaceph-3-em-4-carboxylate (100mg, 0.27mmol) in DMF (2ml) and pyridine (26 μl , 0.32mmol). After work-up the product was purified by chromatography on silica gel eluting with 30 and then 50% ethyl acetate in hexane to yield the *title compound* as a colourless foam (166mg, 72%); ν_{\max} (CH_2Cl_2) 3400, 1770, 1732, 1685, 1612, 1516 and 1374 cm^{-1} ; δ_{H} (CDCl_3) 1.42-2.52 (8H, m), 1.50 (3H, s), 1.53 (3H, s), 3.25 (3H, s), 3.81 (3H, s), 3.82-3.95 (3H, m), 4.96 (1H, dd, J 9.0, 6.8Hz), 5.18 (2H, s), 5.34 (1H, dd, J 6.0, 5.3Hz), 6.41 (1H, d, J 6.0Hz), 6.73 (1H, s), 6.83 (1H, s), 6.89 (2H, d, J 8.7Hz) and 7.27-7.40 (17H, m); m/z (FAB, +ve ion, thioglycerol) 878 (MNa⁺).

b) **4-Methoxybenzyl (6R,7S)-7-[2-(2-aminothiazol-4-yl)-2-(Z)-hydroxyiminoacetamido]-3-[(2S)-tetrahydrofuran-2-yl]-1-carba-1-dethiaceph-3-em-4-carboxylate**

To a solution of 4-methoxybenzyl (6R,7S)-7-[2-(2-tritylaminothiazol-4-yl)-2-
 5 [(Z)-2-methoxyprop-2-yloxyimino]acetamido]-3-[(2S)-tetrahydrofuran-2-yl]-1-carba-1-dethiaceph-3-em-4-carboxylate (160mg, 0.18mmol) in dichloromethane (1.5ml) was added 80% acetic acid (4.4ml) and the mixture stirred at 40°C for 2h. The mixture was diluted with ethyl acetate and washed successively with water (x2), saturated aqueous sodium hydrogen carbonate (x2) and water, dried and then
 10 concentrated *in vacuo*. The residue was triturated with diethyl ether to yield the *title compound* (65mg, 67%); ν_{\max} (KBr) 3418, 3326, 1774, 1716, 1657, 1523 and 1386cm⁻¹; δ_{H} (d₆-DMSO) 1.47-1.62 (2H, m), 1.74-2.08 (4H, m), 2.25-2.35 (2H, m), 3.63-3.87 (3H, m), 3.75 (3H, s), 4.68 (1H, m), 5.13 (2H, s), 5.45 (1H, dd, *J* 8.7, 5.1Hz), 6.67 (1H, s), 6.92 (2H, d, *J* 8.6Hz), 7.12 (2H, br. s, *exch.*), 7.36 (2H, d, *J*
 15 8.6Hz), 9.10 (1H, d, *J* 8.7Hz) and 11.28 (1H, s, *exch.*); *m/z* (CI, +ve ion, ammonia) 542 (MH⁺).

c) **Sodium (6R,7S)-7-[2-(2-aminothiazol-4-yl)-2-(Z)-hydroxyiminoacetamido]-3-[(2S)-tetrahydrofuran-2-yl]-1-carba-1-dethiaceph-3-em-4-carboxylate**

A solution of 4-methoxybenzyl (6R, 7S)-7-[2-(2-aminothiazol-4-yl)-2-(Z)-hydroxyiminoacetamido]-3-[(2S)-tetrahydrofuran-2-yl]-1-carba-1-dethia-
 20 ceph-3-em-4-carboxylate (65mg, 0.12mmol) in dichloromethane (10ml) was added to a solution of aluminium chloride (48mg, 0.36mmol) in anisole (2ml) and dichloromethane (1ml) as described in Example 1(n). After quenching with trisodium citrate (0.5M, 3.7ml) and subsequent work-up, the product was purified by chromatography on HP20SS eluting with water, then 2% THF in water. Fractions containing the product (h.p.l.c. analysis) were combined and freeze-dried to give the *title compound* (14mg, 26%);
 25 ν_{\max} (KBr) 1741, 1593, 1531, 1407 and 1335cm⁻¹; δ_{H} (d₆-DMSO) 1.39-1.53 (2H, m), 1.71-1.90 (3H, m), 2.02-2.13 (3H, m), 3.52-3.80 (3H, m), 4.94 (1H, dd, *J* 7.8, 7.4Hz), 5.25 (1H, dd, *J* 8.1, 5.0Hz), 6.73 (1H, s), 7.18 (2H, br.s, *exch.*) and 11.51 (1H, br.s, *exch.*).

Example 6

35

Sodium (6R,7S)-7-[2-(2-aminothiazol-4-yl)-2-(Z)-difluoromethoxyiminoacetamido]-3-[(2S)-tetrahydrofuran-2-yl]-1-carba-1-dethiaceph-3-em-4-carboxylate

2-(2-Aminothiazol-4-yl)-2-(Z)-difluoromethoxyiminoacetic acid (34mg,

0.14mmol) in DMF (2ml) was treated with methanesulphonyl chloride (11µl, 0.14mmol) and *N,N*-diisopropylethylamine (25µl, 0.14mmol) as described in Example 1(m). This was then treated successively with a solution of 4-methoxybenzyl (6*R*,7*S*)-7-amino-3-[(2*S*)-tetrahydrofuran-2-yl]-1-carba-1-dethiaceph-3-em-4-carboxylate (45mg, 0.12mmol) in DMF (2ml) and pyridine (12µl, 0.14mmol). After work-up the product was purified by chromatography on silica gel eluting with 30,50 and 70% ethyl acetate in hexane to yield the *title compound* as a colourless foam (50mg, 71%); ν_{\max} (CH₂Cl₂) 3400, 1754, 1718, 1685, 1613, 1532 and 1516cm⁻¹; δ_{H} (CDCl₃) 1.51-2.52 (8H, m), 3.78-3.97 (3H, m), 3.81 (3H, s), 4.96 (1H, dd, *J* 8.6, 7.0Hz), 5.17 (2H, s), 5.63 (1H, dd, *J* 7.9, 4.9Hz), 5.93 (2H, br.s, exch.), 6.59 (1H, dd, *J* 73.9, 70.8Hz), 6.88 (2H, d, *J* 8.7Hz) 6.90 (1H, s), 7.33 (2H, d, *J* 8.7Hz) and 8.54 (1H, d, *J* 7.9Hz); *m/z* (CI, +ve ion, ammonia) 592 (MH⁺).


b) Sodium (6*R*,7*S*)-7-[2-(2-aminothiazol-4-yl)-2-(*Z*)-difluoromethoxy-iminoacetamido]-3-[(2*S*)-tetrahydrofuran-2-yl]-1-carba-1-dethiaceph-3-em-4-carboxylate

A solution of 4-methoxybenzyl (6*R*,7*S*)-7-[2-(2-aminothiazol-4-yl)-2-(*Z*)-difluoromethoxyiminoacetamido]-3-[(2*S*)-tetrahydrofuran-2-yl]-1-carba-1-dethiaceph-3-em-4-carboxylate (46mg, 0.078mmol) in dichloromethane (3ml) was added to a solution of aluminium chloride (31mg, 0.23mmol) in anisole (1.4ml) and dichloromethane (0.7ml) as described in Example 1(n). After quenching with trisodium citrate (0.5M, 2.4ml) and subsequent work-up, the product was purified by chromatography on HP20SS eluting with water, then 1,2,4 and 5% THF in water. Fractions containing the product (h.p.l.c. analysis) were combined and freeze-dried to give the *title compound* (25mg, 65%); ν_{\max} (KBr) 1749, 1670, 1595, 1534 and 1388cm⁻¹; δ_{H} (d₆-DMSO) 1.40-1.52 (2H, m), 1.73-1.89 (3H, m), 2.01-2.11 (3H, m), 3.55-3.80 (3H, m), 4.92 (1H, dd, *J* 8.6, 6.8Hz), 5.24 (1H, dd, *J* 8.3, 4.9Hz), 6.99 (1H, s), 7.13 (1H, t, *J* 71.4Hz), 7.36 (2H, br.s, exch.) and 9.52 (1H, d, *J* 8.3Hz); *m/z* (FAB, +ve ion, thioglycerol) 494 (MH⁺), 516 (MNa⁺).

30

CLAIMS

1. A compound of formula (I) or a salt thereof:



5

(I)

wherein:

R^1 is hydrogen, methoxy or formamido;

R^2 is an acyl group, in particular that of an antibacterially active cephalosporin;


- 10 CO_2R^3 is a carboxy group or a carboxylate anion, or R^3 is a readily removable carboxy protecting group or a pharmaceutically acceptable salt-forming group or *in vivo* hydrolysable ester group;

R^4 represents hydrogen or up to four substituents, which may be present on any of the carbon atoms in the ring system shown, selected from alkyl, alkenyl, alkynyl, alkoxy, hydroxy, halogen, amino, alkylamino, acylamino, dialkylamino, CO_2R , $CONR_2$,

- 15 SO_2NR_2 where R is hydrogen or alkyl, aryl and heterocyclyl, which may be the same or different and wherein any R^4 alkyl substituent is optionally substituted by one or more substituents selected from the list from which R^4 is selected;

Y is O, S, SO or SO_2 ; and m is 1 or 2.

- 20 2. A compound as claimed in claim 1 having the formula (Ia) or pharmaceutically acceptable salts or pharmaceutically acceptable *in vivo* hydrolysable esters thereof:




25

(Ia)

wherein R^1 , R^2 , R^4 , m and y are as defined with respect to formula (I) and the group CO_2R^6 is CO_2R^3 where CO_2R^3 is a carboxy group or a carboxylate anion.

3. A compound as claimed in claim 1 or claim 2 wherein R¹ is hydrogen.
4. A compound as claimed in claim 1, 2 or 3 wherein the *in vivo* hydrolysable ester group is the pivaloyloxymethyl ester.
5. A compound as claimed in any one of claims 1 to 4 wherein Y is O or S, in particular O.
6. A compound as claimed in any one of claims 1 to 5 wherein the cyclic ether or thio-ether at the 3-position of the cephalosporin nucleus is unsubstituted or substituted by up to three substituents R⁴, selected from (C₁₋₆) alkyl, for example methyl, (C₁₋₆) alkoxy, for example methoxy, (C₁₋₆) alkoxycarbonyl for example methoxycarbonyl, (C₁₋₆) alkoxy (C₁₋₆) alkyl, for example methoxymethyl, and (C₁₋₆) alkanoyloxy (C₁₋₆) alkyl, for example acetoxymethyl.
7. A compound as claimed in any one of claims 1 to 6 wherein m is 1.
8. A compound as claimed in any one of claims 1 to 7 wherein the cyclic ether at the 3-position of the cephalosporin nucleus is a tetrahydrofuran-2-yl group.
9. Pivaloyloxymethyl (6*R*,7*S*)-7-[2-(2-aminothiazol-4-yl)-2-(*Z*)-methoxyiminoacetamido]-[(*S*)-tetrahydrofuran-2-yl]-1-carba-1-dethiaceph-3-em-4-carboxylate.
10. Sodium (6*R*,7*S*)-7-[2-(2-aminothiazol-4-yl)-2-(*Z*)-methoxyiminoacetamido]-3-[(*S*)-tetrahydrofuran-2-yl]-1-carba-1-dethiaceph-3-em-4-carboxylate,
11. 4-Methoxybenzyl (6*R*,7*S*)-7-phenylacetamido-3-[(*R* and *S*)-tetrahydrofuran-2-yl]-1-carb-1-dethiaceph-3-em-4-carboxylate.
12. 4-Methoxybenzyl (6*R*,7*S*)-7-phthalimido-3-[(*S*)-tetrahydrofuran-2-yl]-1-carba-1-dethiaceph-3-em-4-carboxylate.
13. Sodium (6*R*,7*S*)-7-[2-(2-aminothiazol-4-yl)-2-(*Z*)-prop-2-yloxyiminoacetamido]-3-[(2*S*)-tetrahydrofuran-2-yl]-1-carba-1-dethiaceph-3-em-4-carboxylate.
14. 4-Methoxybenzyl (6*R*,7*S*)-7-[2-(2-aminothiazol-4-yl)-2-(*Z*)-prop-2-yloxyiminoacetamido]-3-[(2*S*)-tetrahydrofuran-2-yl]-1-carba-1-dethiaceph-3-em-4-carboxylate.

15. Sodium (6*R*,7*S*)-7-[2-(2-aminothiazol-4-yl)-2-(*Z*)-hydroxyiminoacetamido]-3-[(2*S*)-tetrahydrofuran-2-yl]-1-carba-1-dethiaceph-3-em-4- carboxylate.
16. 4-Methoxybenzyl (6*R*,7*S*)-7-[2-(2-aminothiazol-4-yl)-2-(*Z*)-hydroxyiminoacetamido]-3-[(2*S*)-tetrahydrofuran-2-yl]-1-carba-1-dethiaceph-3-em-4-carboxylate.
17. Sodium (6*R*,7*S*)-7-[2-(2-aminothiazol-4-yl)-2-(*Z*)-difluoromethoxyiminoacetamido]-3-[(2*S*)-tetrahydrofuran-2-yl]-1-carba-1-dethiaceph-3-em-4- carboxylate.
18. A compound of formula (I) as defined in claim 1 substantially as hereinbefore described with reference to the Examples.
19. A process for the preparation of a compound of formula (I), which process comprises treating a compound of formula (II) or a salt thereof:



(II)

- 20 wherein R^1 , CO_2R^3 , R^4 , m , and Y are as defined in claim 1, wherein any reactive groups may be protected, and wherein the amino group is optionally substituted with a group which permits acylation to take place; with an acid of formula (III) or a N-acylating derivative thereof:



wherein R^2 is the acyl group as defined with respect to formula (I) and wherein any reactive groups may be protected; and thereafter, if necessary or desired, carrying out one or more of the following steps:

30

- i) removing any protecting groups;
- ii) converting the group CO_2R^3 into a different group CO_2R^3 ;
- iii) converting the group R^2 into a different group R^2 ;

- iv) converting the group Y into a different group Y, for example S into SO or SO₂;
 - v) converting the product into a salt or ester.
- 5 20. A pharmaceutical composition comprising a compound of formula (Ia) as defined in claim 2 or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, and a pharmaceutically acceptable carrier.
- 10 21. A pharmaceutical composition as claimed in claim 17 further comprising a β -lactamase inhibitor.
- 15 22. A compound of formula (I) or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, for use as a therapeutic agent, and in particular an *in vivo* hydrolysable ester thereof for use as an orally administrable therapeutic agent.
- 20 23. A compound of formula (I) or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, for use in the treatment of bacterial infections, more particularly an *in vivo* hydrolysable ester thereof for use in the oral treatment of bacterial infections.
- 25 24. A method of treating bacterial infections in humans and animals which comprises the administration of a therapeutically effective amount of an antibiotic compound of the formula (I) or a pharmaceutically acceptable *in vivo* hydrolysable ester thereof, in particular the oral administration of a therapeutically effective amount of an *in vivo* hydrolysable ester.
- 30 25. The use of a compound of formula (I) or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, for the manufacture of a medicament for the treatment of bacterial infections, in particular the use of an *in vivo* hydrolysable ester for the manufacture of a medicament for the oral treatment of bacterial infections.

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC Int.Cl. 5 C07D463/00; A61K31/435											
II. FIELDS SEARCHED <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Minimum Documentation Searched⁷</div> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 30%; border-bottom: 1px solid black;">Classification System</th> <th style="border-bottom: 1px solid black;">Classification Symbols</th> </tr> <tr> <td style="padding: 5px;">Int.Cl. 5</td> <td style="padding: 5px;">C07D ; A61K</td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched⁸</div>			Classification System	Classification Symbols	Int.Cl. 5	C07D ; A61K					
Classification System	Classification Symbols										
Int.Cl. 5	C07D ; A61K										
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹ <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 10%; border-bottom: 1px solid black;">Category⁹</th> <th style="border-bottom: 1px solid black;">Citation of Document,¹¹ with indication, where appropriate, of the relevant passages¹²</th> <th style="width: 10%; border-bottom: 1px solid black;">Relevant to Claim No.¹³</th> </tr> <tr> <td style="vertical-align: top; padding: 5px;">X</td> <td style="padding: 5px;"> WO,A,9 201 696 (BEECHAM GROUP PLC) 6 February 1992 cited in the application see pages 88-93, example 24; claims --- </td> <td style="vertical-align: top; padding: 5px;"> 1-17, 19-25 </td> </tr> <tr> <td style="vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;"> WO,A,9 201 695 (BEECHAM GROUP PLC) 6 February 1992 see claims ----- </td> <td style="vertical-align: top; padding: 5px;"> 1-17, 19-25 </td> </tr> </table>			Category ⁹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	X	WO,A,9 201 696 (BEECHAM GROUP PLC) 6 February 1992 cited in the application see pages 88-93, example 24; claims ---	1-17, 19-25	A	WO,A,9 201 695 (BEECHAM GROUP PLC) 6 February 1992 see claims -----	1-17, 19-25
Category ⁹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³									
X	WO,A,9 201 696 (BEECHAM GROUP PLC) 6 February 1992 cited in the application see pages 88-93, example 24; claims ---	1-17, 19-25									
A	WO,A,9 201 695 (BEECHAM GROUP PLC) 6 February 1992 see claims -----	1-17, 19-25									
<div style="display: flex; justify-content: space-between;"> <div style="width: 48%;"> <p>⁹ Special categories of cited documents : ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 48%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>											
IV. CERTIFICATION <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;"> Date of the Actual Completion of the International Search <div style="text-align: center;">24 AUGUST 1993</div> </td> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;"> Date of Mailing of this International Search Report <div style="text-align: center;">- 6. 09. 93</div> </td> </tr> <tr> <td style="border-bottom: 1px solid black; padding: 5px;"> International Searching Authority <div style="text-align: center;">EUROPEAN PATENT OFFICE</div> </td> <td style="border-bottom: 1px solid black; padding: 5px;"> Signature of Authorized Officer <div style="text-align: center;">CHOULY J.</div> </td> </tr> </table>			Date of the Actual Completion of the International Search <div style="text-align: center;">24 AUGUST 1993</div>	Date of Mailing of this International Search Report <div style="text-align: center;">- 6. 09. 93</div>	International Searching Authority <div style="text-align: center;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center;">CHOULY J.</div>					
Date of the Actual Completion of the International Search <div style="text-align: center;">24 AUGUST 1993</div>	Date of Mailing of this International Search Report <div style="text-align: center;">- 6. 09. 93</div>										
International Searching Authority <div style="text-align: center;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center;">CHOULY J.</div>										

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

GB 9301092
SA 74859

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

24/08/93

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
WO-A-9201696	06-02-92	AU-A-	8222491	18-02-92
		CA-A-	2087967	25-01-92
		CN-A-	1060469	22-04-92
		EP-A-	0540606	12-05-93
		EP-A-	0540609	12-05-93
		WO-A-	9201695	06-02-92

WO-A-9201695	06-02-92	AU-A-	8222491	18-02-92
		CA-A-	2087967	25-01-92
		CN-A-	1060469	22-04-92
		EP-A-	0540606	12-05-93
		EP-A-	0540609	12-05-93
		WO-A-	9201696	06-02-92
